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Abstract 
This study aims to investigate the potential of ethanol-based proliposomes in generating 
paclitaxel-loaded liposome delivery in vitro, by employing various phospholipid 
compositions. 
 
Liposomes prepared using ethanol-based proliposome method successfully generated 
multilamellar vesicles. Three different lipid phases: SPC:Chol, HSPC:Chol or DPPC:Chol 
in 1:1 mole ratio were used in each liposomal formulation to compare their size, size 
distribution, zeta potential, pH and morphology. The size of the liposomes was then 
reduced into nanometre size range.  
 
DPPC-liposomes entrapped 70-85% of the available paclitaxel compared to only 46-75% 
and 26-67% entrapped by liposomes made from SPC and HSPC respectively, using a 
range of paclitaxel concentration. The entrapment efficiency of liposomes was dependent 
on the lipid bilayer properties and ability of paclitaxel to modify surface charge.  
 
In vitro studies revealed that paclitaxel alone was more toxic to U87-MG as well as SVG-
P12 cell lines than liposome formulations. The cytotoxicity of liposomes was dependent 
on their entrapment efficiency and sustained drug release. Thus, DPPC-liposomes had a 
more cytotoxic effect on the cells than SPC and HSPC liposomes. However, Drug-free 
liposomes proved to be non-toxic to the cells, indicating that liposomes might enhance the 
efficacy of the entrapped drug. The properties of different liposome formulations were 
essential in understanding their drug delivery mechanism. 
5 
 
 
List of Abbreviations 
ANOVA Analysis of variance 
APGSP Autocrine and paracrine growth stimulatory pathways 
BBB Blood brain barrier 
BCB Blood cerebrospinal fluid barrier 
BTB Blood tumour barrier 
BV Bevacizumab 
Chol Cholesterol 
CNS Central nervous system 
DMPC Dimyristoylphosphatidylcholine 
DMPG Dimyristoylphosphatidylglycerine 
DMSO Dimethyl sulfoxide 
DPPC Dipalmitoylphosphatidylcholine 
EDTA Ethylenediaminetetraacetic acid 
EE Entrapment Efficiency 
EGFR Epidermal growth factor receptor 
EMEM Eagle’s minimum essential medium 
EPC Egg phosphatidylcholine 
FBS Fetal bovine serum 
FTase Farnesyltransaferase 
GBM Glioblastoma multiforme 
HSPC Hydrogenated soya phosphatidylcholine 
JCV John Cunningham virus 
6 
 
LUV Large unilamellar vesicle 
MAb Monoclonal antibody 
MLV Multilamellar vesicle 
MTD Maximum tolerated dose 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide 
MVL Multivesicular liposome 
OH Hydroxyl group 
OLV Oligolamellar vesicle 
PBS Phosphate buffer solution 
PC Phosphatidylcholine 
PCS Photon correlation spectroscopy 
PDGF Platelet-derived growth factor 
PFS6 Progression-free survival rate by 6 months 
PI Polydispersity index 
PLL Poly-L-Lysine 
PTA Phosphotungstic acid 
RES Reticuloendothelial system 
REV Reverse evaporation vesicle 
SPC Soya phosphatidylcholine 
SUV Small unilamellar vesicle 
SVG-P12 Human glial cell line 
TEM Transmission electron microscopy 
Tm Main phase transition temperature 
U87-MG Human glioblastome cell line 
7 
 
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
VMD Volume median diameter (50% undersize) 
WHO World Health Organization 
ZP Zeta potential 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
Contents 
Title Page……………………………………………………………………………….. 1 
Declaration……………………………………………………………………………… 2 
Acknowledgements……………………………………………………………………... 3 
Abstract…………………………………………………………………………………. 4 
List of abbreviations……………………………………………………………………..5 
Contents………………………………………………………………………………… 8 
List of Figures……………………………………………………………………..........13 
 
CHAPTER 1: 
INTRODUCTION 
 
1.1 Phospholipids………………………………………………………………......17 
1.2 Liposomes………………………………………………………………..…… 19 
1.3 Classification of liposomes…………………………………………………... 21 
1.3.1 Multilamellar vesicles (MLVs)………………………………………….….….22 
1.3.2 Small unilamellar vesicles (SUVs)………………………………………..…...23 
1.3.3 Large unilamellar vesicles (LUVs)…………………………………….….…...24 
1.3.4 Oligolamellar vesicles (OLVs)………………………………………..……….24 
1.3.5 Multivesicular liposomes (MVLs)………………………………….………….25 
1.4 Storage stability of liposomes……………………………………..…..…......25 
1.5 Proliposome technology…………………………………………….…..........26 
1.5.1 Particulate-based proliposomes………………………………………….…….27 
1.5.2 Ethanol-based proliposomes……………………………………….…………..28 
1.6 Glioma……………………………………………………………….…....…..29 
9 
 
1.6.1 Classification according to cell type…………………………………....………30 
1.6.2 Classification according to grade……………………………………….………31 
1.6.3 Classification according to location…………………………………………….32 
1.7 Standard treatment options for glioma……………………………….……...33 
1.8 Anti-angiogenic therapies…………………………………………….……….34 
1.8.1 Antibody therapies………………………………………………………….…..34 
1.8.2  Small molecular anti-cancer agents………………………………….…………35 
1.8.3 Other treatments………………………………………………………………..35 
1.9 Difficulties in CNS drug delivery…………………………………….…........37 
1.10  Paclitaxel……………………………………………………………….…........39 
1.11 Liposomal drug delivery system…………………………………….…....…..41 
1.12 Factors affecting liposome drug delivery…………………………….…..….42 
1.13 Aim of the thesis…………………………………………………..…….……..45 
 
 
CHAPTER 2: 
METHODOLOGY 
 
2.1 Materials……………………………………………………………….…..….47 
2.2 Methods…………………………………………………………………...…..49 
2.2.1 Preparation of liposomes using the ethanol-based proliposome method….…. 49 
2.2.2 Size reduction of liposomes……………………………………………….…..49 
2.2.3 Laser diffraction size analysis for liposomes……………………………….....50 
2.2.4 Photon correlation spectroscopy for liposomes…………………………..…...51 
2.2.5 Zeta potential analysis of liposomes…………………………………………..51 
10 
 
2.2.6 Transmission Electron Microscopy (TEM)………….………….……….……51 
2.2.7 Determination of drug entrapment efficiency……………….….……....…….52 
2.2.8 Cell culture technique……………………………………………….…...….. 53 
2.2.9 Sub-culturing of the cells………………………………………….….…..…..53 
2.2.10  Calculation of cell viability………………………………………….…..….. 54 
2.2.11 Seeding of 96-well plates………………………………………………..…...55 
2.2.12 Evaluation of cytotoxicity using colourimetric tetrazolium-based MTT  
           Assay…………………………………………………….……………...…….56 
2.2.13 Statistical analysis……………………………………………….…….….…..57 
 
 
CHAPTER 3: 
CHARACTERISATION OF LIPOSOMES GENERATED FROM ETHANOL-
BASED PROLIPOSOMES 
 
3.1 Introduction……………………………….……………………………….59 
3.2 Results and Discussion…………………………..……………….…..…...59 
3.2.1 Size analysis of liposomes before sonication…………..…………...….…..59 
3.2.2 Size distribution (Span) of liposomes before sonication……………………62 
3.2.3 Zeta potential analysis of liposomes before sonication………..……… .… 63 
3.2.4 Size analysis of the liposomes after probe sonication……………….….….64 
3.2.5 Polydispersity Index (PI) of the liposomes after probe sonicatio…..….…..66 
3.2.6 Zeta potential analysis of liposomes after probe sonication………...….…..67 
3.2.7 Morphology of the liposomes……………………………………….....…..68 
3.2.8 pH measurement of liposome formulations………………….…….….…...72 
11 
 
3.2.9 Entrapment efficiency of paclitaxel in liposomes………….……….………..73 
3.2.10 Amount of paclitaxel entrapped in liposomes………………….……….…....76 
3.3 Conclusion……………………………………………………………...…...80 
 
CHAPTER 4: 
CYTOTOXICITY STUDIES OF LIPOSOMAL FORMULATIONS ON GLIOMA 
AND GLIAL CELLS IN VITRO 
 
4.1 Introduction…………………………………………………………..…….84 
4.2 U87-MG cells………………………………………………………..…...…85 
4.3 SVG-P12 cells………………………………………………………..……..86 
4.4 Results and Discussion………………………………………...….…..……87 
4.4.1 Introduction…………………………………………………...……......….. 87 
4.4.2 Growth curve of U87-MG cells…………………………………..…...…… 88 
4.4.3 Growth curve of SVG-P12 cells……………………………….….…....…...90 
4.4.4 Effects of liposomes, paclitaxel and controls on U87-MG cells……...…….92 
4.4.5 Effects of liposomes, paclitaxel and controls on SVG-P12 cells.…............. 98 
4.5 Conclusion………………………………………………………......….…104 
 
 
CHAPTER 5: 
GENERAL CONCLUSIONS AND FUTURE STUDIES  
 
5.1 Introduction……………………………………………….….....…....….108 
5.2 Charactersation of liposomes before sonication…………...…......…....109 
12 
 
5.3 Characterisation of liposomes after sonication………….….….….…109 
5.4 pH of liposome formulations…………………………………..……....110 
5.5 Entrapment efficiency of paclitaxel in liposomes…………….…...….110 
5.6 Tissue culture findings………………………………………..…..……112 
5.7 Future studies…………………………………………………….……..115 
 
 
CHAPTER 6: 
REFERENCES                                                                                                   116 
 
 
 
 
 
 
 
 
 
 
 
13 
 
List of Figures 
Figure No. Title Page No. 
1.1 Chemical structure of phosphatidylcholine 17-18 
1.2 Mechanism of liposome formation 19 
1.3 Chemical structure of cholesterol 21 
1.4 Classification of liposomes 22 
1.5 A schematic representation of the blood-brain barrier 38 
1.6 Chemical structure of paclitaxel 39 
3.1 
Size of liposomes generated from ethanol-based proliposome 
formulations with a range of paclitaxel concentrations 
61 
3.2 
Size distribution of liposomes generated from ethanol-based 
proliposome formulations with a range of paclitaxel 
concentrations 
62 
3.3 
Zeta potential of liposomes generated from ethanol-based 
proliposome formulations with a range of paclitaxel 
concentrations 
64 
3.4 Size of liposomes after probe sonication 65 
3.5 PI of liposomes after probe sonication 66 
3.6 Zeta potential of liposomes after probe sonication 67 
3.7  
TEM of SPC: Chol (1:1) liposomes containing 1 mg/ml 
paclitaxel concentration after size reduction 
69 
 
 
3.8 
TEM of HSPC: Chol (1:1) liposomes containing 1 mg/ml 
paclitaxel concentration after size reduction 
70 
14 
 
3.9 
TEM of DPPC: Chol (1:1) liposomes containing 1 mg/ml 
paclitaxel concentration after size reduction 
 
71 
3.10 pH of liposomes after probe sonication 73 
3.11 Calibration curve of paclitaxel 74 
3.12 Entrapment efficiency of liposomes by UV method 75 
3.13 The amount of paclitaxel entrapped per 10 ml of formulation 77 
4.1 
Electron Micrograph of U87-MG cells showing epithelial 
morphology in low and high confluency 
86 
4.2 
Growth curve of U87-MG cell line for 7 day period 
 
89 
4.3 
Inverted light microscope photographs of U87-MG cells, on 
day 7 of growth curve, with different seeding densities 
90 
4.4 
Growth curve of SVG-P12 cell line for 7 day period 
 
91 
4.5 
Inverted light microscope photographs of SVG-P12 cells, on 
day 7 of growth curve, with different seeding densities 
91 
4.6 
Viability of U87-MG cell line tested with increasing 
concentrations of different drug compounds in 96-well plates 
93 
4.7 
Inverted microscope photographs of the viability of U87-MG 
cells treated with paclitaxel-liposomal formulations and 
paclitaxel 
95 
4.8 
IC50 of paclitaxel-loaded liposomes, paclitaxel and PLL 
against U87-MG cells. 
96 
4.9 
Viability of SVG-P12 cell line tested with increasing 
concentrations of different drug compounds in 96-well plates 
99 
15 
 
4.10 
Inverted microscope photographs of the viability of SVG-P12 
cells treated with paclitaxel-liposomal formulations and 
paclitaxel 
101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1: 
 INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
17 
 
 
1.1 Phospholipids 
Phospholipids are essential components in the formulation of liposomes. They are 
amphipathic molecules which consist of hydrophilic (polar) headgroups and hydrophobic 
(non-polar) hydrocarbon chains (New, 1990a). The polar headgroups are made up of 
diverse molecules and non-polar hydrocarbon chains can differ in length and degree of 
saturation, resulting in different types of phospholipids, which may affect the bilayer 
permeability and surface charge of the resulting liposomes (Perrie and Rades, 2010). 
Phospholipids can be divided into synthetic phospholipids and natural phospholipids. 
Dimyristoylphosphatidylcholine (DMPC) and dipalmitoylphosphatidylcholine (DPPC) are 
examples of synthetic phospholipids. Natural phospholipids include egg 
phosphatidylcholine (EPC) and soya phosphatidylcholine (SPC). Figure 1.1 shows the 
chemical structure of SPC, hydrogenated soya phosphatidylcholine (HSPC) and DPPC.  
 
 
Fig.1.1 Chemical structure of phosphatidylcholines (Source: Zhao et al., 2004 ) 
Soya phosphatidylcholine (SPC) 
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Hydrogenated soya phosphatidylcholine (HSPC) 
 
 
Dipalmitoylphosphatidylcholine (DPPC) 
 
 
Phosphatidylcholines (PCs) are primarily used phospholipids in liposome preparation. PCs 
are neutral or zwitterionic with pH ranging from strongly acidic to strongly alkaline. PCs 
are water insoluble lipids so they self-assemble in aqueous media, with hydrocarbon chains 
being oriented away from the aqueous phase. Mechanical agitation will quickly cause lipid 
bilayers to form liposomes (New, 1990a) (Fig. 1.2). 
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Fig. 1.2. Mechanism of liposome formation (Source: Avanti Polar Lipids, Inc.) 
 
 
 
1.2 Liposomes 
Liposomes are microscopic phospholipid bilayer vesicles having a size range between 25 
nm and 20 µm. Liposomes were discovered in 1960s by Dr Alec Bangham (Bangham et 
al., 1965; Torchilin, 2005). Liposomes have the ability to entrap hydrophilic therapeutic 
agents in their aqueous central compartment and hydrophobic therapeutic agents (ligands, 
polymers or macromolecules) can be entrapped within their phospholipid bilayers or can 
be attached to the liposome surfaces (Torchilin, 2005). The advantage of liposomes is that, 
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they are biodegradable and non-toxic because they are made of naturally occurring 
materials that are present in the biological membranes (Naderkhani, 2011). Drugs loaded 
in liposomes may exhibit a continuous release or targeted delivery in manners that are 
dependent on liposome size, bilayer composition and liposome surface properties.  
 
The mechanism suggested by Lasic (1988) described the formation of liposomes. In this 
experiment, the aqueous phase was added to the dry phospholipid film that led to the 
hydration of outer monolayer to exceed that of the inner layers. The increase in hydration 
resulted in increasing the surface area of the polar heads and caused the formation of 
“blisters” (Lasic, 1988, Saupe, 1977). These blisters were converted into phospholipid 
bilayers which further developed into tubular fibrils. This process increased the contact 
area of the lipid with the aqueous phase. The bilayer sheets then consisted of hydrophobic 
moieties exposed to the thermodynamically unstable aqueous phase. The bilayers may be 
compelled to seal off and form multilamellar vesicles (Lasic, 1988). Liposome bilayers 
exhibit a gel phase (well-ordered) below the lipid phase transition temperature (Tm) and a 
disorderly fluid phase above the Tm of the phospholipid employed. Therefore, the 
hydration procedure for liposome formation should be carried out at a temperature above 
the phase transition temperature (Tm) of the selected phospholipid (Lian and Rodney, 
2001; Elhissi et al., 2006). 
 
The incorporation of cholesterol into the lipid bilayer has demonstrated a significant effect 
on the properties of liposomes. Cholesterol enhances the stability of the lipid bilayers by 
forming highly ordered and rigid phase with fluid-like characteristics depending on the 
type of phospholipid involved in the liposome (Lee et al., 2005). The four hydrocarbon 
rings makes the molecular structure of cholesterol strongly hydrophobic while at the same 
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time the hydroxyl group (OH) makes the end of cholesterol weakly hydrophilic (Fig. 1.3). 
The molar ratio of phospholipid to cholesterol in lipid bilayers commonly used in the 
liposome formation is 1:1 respectively (Cooper and Hausman, 2009). 
 
 
Fig.1.3. Chemical structure of cholesterol (Source: Sigma Aldrich, UK) 
 
 
 
1.3 Classification of liposomes 
Liposomes are classified depending on their morphology into multilamellar liposome 
vesicles (MLVs), small unilamellar vesicles (SUVs), large unilamellar vesicles (LUVs) 
oligolamellar vesicles (OLVs) and multivesicular liposomes (MVLs) (Fig. 1.4).  
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Fig. 1.4. Classification of liposomes (Adapted from Elhissi et al., 2006) 
 
 
1.3.1 Multilamellar vesicles (MLVs) 
Multilamellar liposome vesicles (MLVs) are commonly referred to as “conventional 
liposomes” and consist of several concentric phospholipid bilayers, and have a typical size 
range between 0.1 µm and 20 µm (Fig. 1.4). They are prepared by the thin film hydration 
method. A thin film of lipid is prepared by dissolving the phospholipid with or without 
cholesterol in an organic solvent (e.g. chloroform) within a round bottom flask. 
Evaporation of the organic solvent under vacuum using rotary evaporator causes the 
formation of a thin film of lipid on the inner walls of the flask. Addition of water with 
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shaking causes the formation of MLVs (Bangham et al., 1965; Elhissi et al., 2006). This 
procedure is carried out above the phase transition temperature (Tm) of the phospholipid. 
The solvent evaporated by rotary evaporator is collected via a condenser for disposal or 
reuse.  
 
 
1.3.2 Small unilamellar vesicles (SUVs) 
A small unilamellar vesicle (SUV) consists of a single phospholipid bilayer which makes a 
liposome having a size that ranges between 25 and 100 nm (Fig. 1.4). Batzsri and Korn 
(1973) prepared SUVs by injection of an ethanolic solution of phospholipid into the 
aqueous phase above the Tm of the phospholipid, with appropriate dilution and mixing. 
Generally, SUVs are manufactured by probe sonication of MLVs dispersions. As an 
alternative to the method introduced by Batzsri and Korn (1973), probe sonication of large 
liposomes can generate SUVs (New, 1990b). In this method, the probe of the sonicator is 
immersed in the liposome dispersion and operated at the highest frequency to disrupt the 
MLVs to form SUVs. The probe is composed of an inert or biologically friendly metal like 
titanium. The probe is tuned to the oscillating electric current frequency such that the 
probe can oscillate in harmony with the liposome vesicles. Probe sonication can generate 
extensive heat rapidly due to the high power input into preparation by the tip of the probe. 
Due to increased gas exchange and high temperature, there is high risk of lipid bilayer 
degradation. Thus, while processing heat labile samples such as liposomes, the samples 
must be kept cold and the sonication must be performed in short burst intermitted with 
cooling periods (Santos et al., 2009). 
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1.3.3 Large unilamellar vesicles (LUVs) 
Large unilamellar vesicles (LUVs) consist of a single phospholipid bilayer, similar to 
SUVs but having a larger size that falls in the range of 0.1 µm to 1 µm (Fig. 1.4). These 
liposomes are known to provide high hydrophilic drug entrapment compared to that of 
MLVs. LUVs are prepared by injection of an ethereal phospholipid solution into an 
aqueous phase previously heated above the Tm of the injected phospholipid (Deamer and 
Bangham, 1976). The drawbacks associated with this method are that the population is not 
homogenous (70-190 nm) and the disclosure of encapsulated drug to high temperature or 
organic solvents (Chauhan et al., 2012; Scieren et al., 1978). In another method, Kirby and 
Gregoriadis (1984) prepared dehydrated-rehydrated vesicles by mixing aqueous drug 
solution and suspension of drug-free SUVs, followed by freeze-drying. The SUVs convert 
into LUVs which may typically have a vesicle size of 1 µm or less after rehydration.  
 
1.3.4 Oligolamellar vesicles (OLVs) 
MLVs possessing only two or three phospholipid bilayers are known as oligolamellar 
vesicles (OLVs) (Fig. 1.4). Szoka and Papahadjopoulos (1978) introduced a method 
known as Reverse phase evaporation method. This method produces a mixture of OLVs 
and LUVs and they are termed as reverse evaporation vesicles (REVs). REVs provide up 
to 62% of entrapment of the aqueous phase. Alternatively, ethanol-based proliposomes 
may generate oligolamellar liposomes (Perrett et al., 1991). Ethanol-based proliposomes 
are concentrated ethanolic mixtures of phospholipids that generate liposomes upon 
addition of aqueous phase and shaking (Perrett et al., 1991). 
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1.3.5 Multivesicular liposomes (MVLs) 
When a large liposome vesicle similar in size to an MLV, enclose a group of liposomes, 
then the subsequent vesicle is known as multivesicular liposome (MVL) (Kim et al., 1983) 
(Fig. 1.4). According to the experiments conducted by Kim et al., (1983) high 
encapsulation (about 89%) of hydrophilic drugs was achieved. The drug was dissolved in 
the aqueous phase of water-in-oil emulsion, where oil phase consisted of phospholipid, 
neutral oil such as triolein and organic solvents. MVLs were formed by the addition of 
aqueous sucrose solution and aliquots of the emulsion, followed by the evaporation of the 
organic solvent at warm temperature. MVLs prepared by this method have advantages 
over MLVs prepared by the thin-film method as MVLs may have high storage stability 
and easy production scale up (Kim et al., 1987).  
 
 
1.4 Storage stability of liposomes 
Liposome formulations using synthetic or natural phospholipids (e.g. phosphatidylcholine) 
aims to reduce drug toxicity and increase the accumulation of drug at the target site (Lian 
and Rodney, 2001). However, liposomes are unstable as liquid dispersions and the liability 
of the phospholipids to degrade by oxidation or hydrolysis can cause liposome aggregation 
followed by leakage of entrapped material. Lipid hydrolysis may be increased at certain 
pH values of the dispersion (Grit et al., 1993). Oxidation may be reduced by incorporation 
of antioxidants (Hunt and Tsang, 1981) or by reduction of storage temperature to 4°C 
(Hernandez-Caselles et al., 1990).  
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For the stability of liposomes, freeze-drying of the liposome aqueous dispersions may be 
performed. This may however lead to a destabilising effect on the bilayers, which can be 
minimised by the addition of cryoprotectants such as trehalose or sucrose (Crowe et al., 
1987) before freezing. Van Winden and crommelin (1997) suggested a method to maintain 
the residual water content in the liposomes at a minimum level to prevent the increase of 
vesicular size on rehydration and increase the shelf-life and stability of the lyophilised 
liposomes and formulations.  
 
Spray drying is another method employed to increase the storage life of liposomes. 
Skolka-Basnet et al. (2000) applied one-step spray-drying method on liposomes entrapping 
verapamil or metronidazole with or without cyclodextrin. They observed that the 
entrapment efficiency and size distribution of liposomes measured before drying were still 
maintained after one year of storage of the liposome powder at 4°C. 
 
 
1.5 Proliposome technology 
Proliposome technologies such as particulate-based proliposomes (Payne et al., 1986a, b) 
and ethanol (solvent)-based proliposomes (Perrett et al., 1991) have been suggested to 
deliver convenient and economic options when compared to spray-drying or freeze-drying 
of liposomes. Proliposomes can also overcome the difficulty of manufacturing of 
liposomes on a large scale due to the instability problems (liability of phospholipid to 
hydrolysis, oxidation and subsequent loss of entrapped drug) high costs and unsuitability 
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of scaling up of liposomes prepared from conventional methods e.g. thin film method 
(Kensil and Dennis, 1981; Grit et al., 1989; Hunt and Tsang, 1981). 
 
 
1.5.1 Particulate-based proliposomes 
Particulate-based proliposomes involve carbohydrates as soluble carrier materials layered 
with phospholipids to form MLVs upon addition of water above Tm (Payne et al., 1986). 
This type of proliposome is prepared by attaching a flask comprising the carrier particles 
to a rotary evaporator. The organic phase of lipid is added through a feed-line in a portion-
wise manner to coat the carrier, under low pressure. Evaporation of the organic solvent 
under vacuum using rotary evaporator causes the formation of particulate-based 
proliposomes. The carrier particles involved in the formation of these proliposomes may 
be sodium chloride, lactose, fructose, glucose (Payne et al., 1986a), mannitol (Zhang and 
Zhu, 1999), or sorbitol (Payne et al., 1986a, b; Payne et al., 1987; Lee et al., 1995, 1996; 
Ahn et al., 1995a, b; Chung, 1999; Hwang et al., 1997; Song et al., 2002; Jung et al., 2000; 
Elhissi et al., 2006). Another type of particulate-based proliposome, named bead-based 
proliposomes, was prepared in order to scale up proliposomes using fluidised-bed coating 
(Kumar et al., 2001; Chen and Alli, 1987; Katare et al., 1990).  
 
Liposomes prepared from this method have high entrapment efficiency for lipophilic 
compounds such as nicotine (around 45 to 58%) (Chung, 1999), Amphotericin B (100%) 
(Payne et al., 1987), salmon calcitonin (20%) (Song  et al., 2002), ciprofloxacin (96%) and 
CM3 peptide (100%) (Desai et al., 2002). However, the entrapment efficiency of 
hydrophilic materials was generally low (in the range of 4 to 10%) but the entrapment can 
be maximised by increasing the phospholipid to drug ratios (Ahn et al., 1995 a). 
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1.5.2 Ethanol-based proliposomes 
Ethanol-based proliposomes are ethanolic lipid solutions which, depending on the 
hydration procedure, generate oligolamellar liposomes (Perrett et al., 1991) or 
multilamellar vesicles (Turánek et al., 1997), upon addition of aqueous phase above the Tm 
of the employed lipid. Agitation of the liposome formulation may produce MLVs and 
SUVs while non-agitated samples may form LUVs with intermittent MLVs (Deo et al., 
1997).  
 
Liposomes prepared from this method have been shown to be responsible for high 
entrapment efficiency for hydrophilic drugs. The entrapment efficiency ranged from 65 to 
80% depending on the composition of phospholipid (Perrett et al., 1991) and 30 to 85% 
depending on the hydration method (Turánek et al., 1997). There was a small effect of the 
hydration rate on the entrapment efficiency of carboxyfluorescein (CF), however hydration 
temperatures employed was important in influencing the entrapment efficiency as high 
temperature (60°C) provided an effective entrapment (approx. 80%) rather than at low 
temperature (20°C) where the entrapment was around 50% (Turánek et al., 1997). 
These liposomes may provide different entrapment efficiency for different compounds. For 
instance, they have showed entrapment of 69% and 65% for antibiotics gentamycin and 
neomycin respectively, 81% for CF, 85%, 62% and 87% for β-D-GlcNAc-norMurNac-L-
Abu-D-isoGln, muramyl dipeptide and admanttylamide dipeptide immunomodulators 
respectively (Turánek et al., 1997). Hydrophobic drugs may also have high entrapment 
efficiencies with these liposomes. Entrapment efficiency of 93 to 98% was observed for 
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levonorgestrel depending on type of alcohol employed in the formulation (Deo et al., 
1997). 
 
 
1.6 Glioma 
Cancer, clinically known as malignant neoplasm, includes a wide range of diseases 
involved in uncontrollable and abnormal cell growth. Glioma represents the most common 
cancer of the central nervous system (CNS), accounting for about 46% of intracranial 
tumours. Glioma is a type of tumour that is derived from glial cells and it includes tumours 
of oligodendrial, astrocytic, ependymal or a mixed source of cells (Danyu et al., 2011; 
Riemenschneider et al., 2010). The average survival probability in patients with glioma is 
14.6 months (Danyu et al., 2011). The underlying causes of glioma have not yet been 
identified, but amongst the reported environmental risk factors is the exposure to high-
intensity ionising radiation. However other factor that is relevant to the victims of glioma 
have been reported, for instance 5-10% of glioma cases possess genetic predisposition 
(Riemenschneider et al., 2010).  
 
According to the World Health Organisation (WHO), there are 100 different types of brain 
tumours depending on the pathological diagnosis. Gliomas may originate in the brain, 
central nervous system or from elsewhere hence, they can be classified into either primary 
or secondary tumours (Lesniak and Brem, 2004). 
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1.6.1 Classification according to cell type 
Gliomas are termed according to the histological features of the cell. These features are: 
Ependymomas, astrocytomas, oligodendrogliomas and mixed gliomas. Ependymomas 
ascend from ependymal cells lining the brain ventricles and center of the spinal cord. They 
are greyish, soft red tumours which contain mineral calcification or cysts. They account for 
only 2-3% of all primary tumours but are most common in children under the age of three. 
Treatment options include surgical removal of these tumours and radiation therapy 
(Hayashi et al., 2012).  
 
Astrocytoma tumours arise from astroglia, star-shaped glial cells, which form the 
supportive tissue in the brain. These tumours have been graded by the World Health 
Organisation (WHO) (Section 1.6.2) to identify the normal and abnormal characteristics of 
tumour cells.  
 
Oligodendrogliomas are tumours that arise from oligodendrocytes, making up the 
supportive tissue of the brain. The location of the tumour is in the cerebral hemisphere. 
This tumour frequently occurs in young, middle-aged adults and may be found in children. 
Standard treatments include surgery, radiation therapy and chemotherapy. A combination 
of radiation and chemotherapy may also be included using temozolomide or PCV 
[procarbazine, CCNU (Lomustine) and Vincristine] (Levin et al., 1980).  
 
31 
 
Oligoastrocytomas are a type of brain tumour which arises from mixed glial source. They 
are commonly found in the temporal or frontal lobes and anywhere in the cerebral 
hemispheres of the brain (Viswanathan et al., 2012). 
 
 
1.6.2 Classification according to grade 
Gliomas could be further classified according to their grades based on a system that has 
been introduced by the WHO. Grade - I glioma is known to be non-invasive, least 
advanced, least aggressive and have good prognosis. Low grade gliomas (WHO grade II) 
are not benign but can be differentiated (non-anaplastic). This type of glioma represents 
moderately increased cellular density, infrequent nuclear atypia, and absence of mitotic 
activity, necrosis and endothelial proliferation. They tend to be growing slow and 
infilterating tumours (ability to grow in the surrounding tissue). The most common type of 
tumour in childhood is the low grade astrocytoma with 10-15% diagnosis of high grade 
gliomas (Pollack, 1994) which makes a total of approximately 50-70 cases of glioma per 
year in the U.K.  
 
Grade-II gliomas can be removed by surgery, however some microscopic cells may 
remain behind causing the tumour to grow again in some years. Radiation therapy and 
chemotherapy may also be suggested for the treatment. This type of glioma generally has 
good prognosis (survival rate of up to 5 years) and regular attention on the recurrence of 
symptoms is necessary (Marquet et al., 2007). 
 
Grade III astrocytomas are undifferentiated (anaplastic) group of abnormal cells having 
tentacle-like projections. The tumour grows into the surrounding tissue completely which 
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renders them difficult to be removed by surgery. The histological features of this type of 
glioma represent increased cellular density, distinct nuclear atypia, marked mitotic activity, 
and absence of necrosis and endothelial proliferation (Marquet et al., 2007). The treatment 
options are based on the location and size of the tumour. Surgery and biopsy may be 
carried for diagnosis and reduction of symptoms.  
 
Grade IV astrocytoma is also known as glioblastoma multiforme (GBM) or high-grade 
glioma, which is the most aggressive and frequent primary brain tumour. These tumours 
represent up to 50% of all primary brain tumours and 20% of all intracranial tumours with 
poor prognosis (Danyu et al., 2011; Riemenschneider et al., 2010). GBM is generally 
found in the cerebral brain hemispheres, but they can also be found in spinal cord. This 
type of glioma is capable of rapid growth causing symptoms such as increased brain 
pressure, seizures, headaches, loss of memory and behavioural changes. It is the most 
malignant type of brain tumour with 60-75% of astrocytic tumours and 12-15% of all 
brains tumours. GBM has tendency to migrate into normal brain cells and extremely 
infiltrative property making them very difficult to be treated by standard therapies except 
for increasing the survival time of the patients (Zhang, et al., 2012). Chemotherapeutic 
options are same as those used for treatment of grade-III gliomas.  
 
 
1.6.3 Classification according to location 
Gliomas can also be classified according to their location, being above or below the 
tentorium that separates the cerebrum from the cerebellum. Supratentorial is located in the 
cerebrum. This affects mostly 70% of infected adults. By contrast, infratentorial is located 
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in the cerebellum. This affects mostly 70% of infected children. Pontine is located in the 
pons of the brain stem which is also another area for tumour growth.  
 
 
1.7 Standard treatment options for glioma 
Current standard remedy for newly diagnosed patients is surgery followed by radiation 
therapy and using the adjuvant chemotherapeutic agent temozolomide which is an oral 
alkylating agent (Rahman et al., 2010). Several forms of radiation therapies such as 
conventional external beam radiation, stereotactic radiation and conformal may be carried 
out depending on the progression of the tumour. Chemotherapeutic options include 
Carmustine (BCNU), Lomustine (CCNU), procarbazine, temozolomide and cisplatin. In 
some cases, biodegradable wafers of BCNU (Gliadel
®
) are also implanted in the tumour 
cavity for targeted delivery in case of high-grade gliomas (Bota et al., 2007). 
 
These treatment options have side-effects which may lead to neurological disabilities. 
Pathways that control the angiogenesis (formation of new blood vessels) are usually 
observed in both paediatric and adult tumours (Liang et al., 2005). Clinical studies have 
reported that GBM is highly vascularized and dependent on angiogenesis. The structure of 
vasculature in GBM is tortuous, disorganised and functional abnormality leading to 
acidosis, disruption of the BBB, hypoxia, increased interstitial pressure and tissue necrosis. 
Vascular endothelial growth factor-A (VEGF-A) is the principle growth factor expressed 
by GBM cells. Its receptor, vascular endothelial growth factor receptor-2 (VEGFR-2) is 
known to mediate signal transduction, which is expressed in the endothelial cells 
associated to glioma. Anti-angiogenic therapies may restore normal function of blood 
vessels, increase oxygen delivery and enhance the production of cytotoxic agents to inhibit 
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tumour progression and therapeutic resistance (Jain et al., 2009). Strategies for targeting 
tumour angiogenesis and tumour endothelial cells that aim at tumour vasculature 
regression have been employed (Rahman et al., 2010; Palanichamy et al., 2006; Chi et al., 
2009).  
 
 
1.8 Anti-angiogenic therapies 
1.8.1 Antibody therapies 
Bevacizumab (BV) is an IgG1 recombinant humanised monoclonal antibody (MAb) that 
acts against free vascular endothelial growth factor-A (VEGF-A) in the circulation, 
preventing activation of pro-angiogenic pathway upon attachment to VEGF receptor. BV 
was the first anti-angiogenic therapy approved by the Food and Drug Administration 
(FDA) for the treatment of recurrent glioblastoma multiforme (rGBM) in 2009 (Chi et al., 
2009). Originally, bevacizumab was developed for the treatment of non-small cell lung 
and metastatic cancers. This antibody has also been approved by the European Medical 
Agency for its use in the treatment of kidney and breast cancer. BV has been shown to 
produce approx. 20 to 40% response rate and increase progression-free survival rate by 6 
months (PFS6) to approx. 30 to 50% (Perry et al., 2010), which is greater than 
temozolomide producing only 21% PFS6 (Yung et al., 2000). BV therapy causes 
significant reductions in peritumoral oedema often decreasing the need of high dose intake 
and corticosteroid use. BV can be very effective in treating brain tumours. However, the 
adverse effects of BV include hypertension, bowel perforation and renal thrombotic 
microangiopathy (Eremina et al., 2011). 
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1.8.2 Small molecule anti-cancer drugs 
Small molecule anticancer agents are comparatively low molecular weight compounds 
with improved penetration through the blood brain barrier. These compounds may act on 
multiple molecularly related receptors tyrosine kinases (Rahman et al., 2010). 
 
 
1.8.3 Other Treatments 
Cediranib is an indole-ether quinazoline that inhibits all subtypes of the VEGF receptors; 
some platelet derived growth factors (PDGF) and c-Kit receptors. Sorafenib is another 
compound that inhibits a broad range of kinases. Other tyrosine kinase inhibitors include 
imatinib, erlotinib and gefitinib (Rahman et al., 2010). Other therapies such as molecular 
targeted drugs may interfere with intracellular signalling pathways and various drug 
carriers may target specific cancer cell surface molecules. Examples include various types 
of epidermal growth factor receptor (EGFR) inhibitors like cetuximab. Drugs that target 
intracellular molecules include farnesyltransferase (FTase) inhibitor tipifarnib and 
rapamycin inhibitor temsirolimus (Van Meir, et al., 2010; Ohgaki and Kleihues, 2007; 
Furnari et al., 2007).  
 
Antisense therapies like protease inhibitors (e.g. marimastat and tamoxifen) are also 
included to block the signalling of malignant cells to produce proteins for tumour cell 
reproduction and alter the ability of malignant cells to interfere with the normal cells. 
Immunotherapeutic options such as immunotoxins (e.g. diptheria) are also available to 
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inhibit tumour growth. Interferons also inhibit tumour growth by stimulating the immune 
system.  
 
Gene therapy is another method for inhibiting tumour growth by making tumour cells 
liable to drug therapy and restoring the normal function of tumour suppressors (Iwami et 
al., 2010). microRNAs are conserved sequences of 20-23 base pair long. They may be 
effective in controlling the angiogenic process by binding to messenger RNA via 
complementary sequences (Rahman et al., 2010). DNA can also be delivered to the 
patients by altering the tumour cells in vitro and transferring them back into the patient. It 
can also be delivered by injecting the tumour mass along with a vector that carries a gene 
for encoding cytokines or toxins. Another approach is when the vector is systematically 
administered while the gene is delivered locally to the target cells. However, the major 
drawbacks in gene therapy are low-efficiency of available gene-vectors and lack of 
selectivity of the vectors for targeted delivery (Lesniak and Brem, 2004). 
 
Despite of these advances, the types of drugs used for different targets have been mostly 
disappointing in patients, with non-demonstrated survival benefits. Poor intratumoral 
accumulation due to the blood brain barrier and high interstitial pressure restricting the 
amount of drug to exert its effects on the cancer cells which is considered a major problem 
that limits the therapeutic efficacy (Van Meir, et al., 2010).  
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1.9 Difficulties in CNS drug delivery 
The treatment options for gliomas have been inadequate due to the lack of efficient drug 
delivery methods. The effective therapies for glioma are restricted due to the presence of 
the blood brain barrier (BBB), the blood-tumour barrier (BTB) and the blood-
cerebrospinal fluid barrier (BCB). The tight junctions in the BBB do not allow the 
exchange or influx of molecules or ions from the systemic circulation to the CNS (Fig. 
1.5). The impermeability of the cerebral capillary endothelium to the ions, peptides and 
macromolecules imposes a challenge to researchers at improving drug delivery by 
focusing on augmenting the permeability of drug through the BBB (Lesniak and Brem, 
2004).  
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Fig.1.5. A schematic representation of the blood-brain barrier.  (Source: Drappatz et 
al., 2007) 
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1.10 Paclitaxel 
Paclitaxel, a diterpinoid is a promising anti-tumor drug having poor water solubility but 
can be dissolved in organic solvents. It was first isolated from Western yew (Taxus 
brevifolia; Family Taxaceae) in 1967, having molecular formula C47H51NO14 and 
molecular weight of 853 Da (Wani et al., 1971; Singla et al., 2001; Panchagnula, 1998) 
(Fig. 1.6).  
 
Fig. 1.6. Chemical Structure of Paclitaxel (Source: Singla et al., 2002) 
 
 
Paclitaxel has been shown to have a significant anti-cancer activity against ovarian 
carcinoma, head and neck cancers, breast cancer, lung cancer and AIDS related Kaposi’s 
sarcoma (Rowinsky and Donehower, 1995). Paclitaxel is considered as significant in 
chemotherapy advancement for the past 20 years and is the first of a new class of 
microtubule stabilizing agents. It has been known to cause apoptosis by disruption of 
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normal tubule function necessary for cell division (Sharma and Straubinger, 1994; 
Hennenfent and Govindan, 2006; Slavin and Chhabra, 2007). Paclitaxel also causes 
induced apoptosis of cancer cells by binding to Bcl-2 (B-cell leukemia 2) apoptosis 
stopping protein and arresting their function. (Henley and Isbill, 2007). The potential 
efficacy of paclitaxel against brain tumours have also been reported (Tseng and Bobola, 
1999).  
 
Tissue culture studies have reported the cell kinetic effects of paclitaxel resulting in 
proliferation of cells during G2 or M phase of cell cycle (Schiff and Horwitz, 1980). It also 
showed significant cytotoxic effects against various human malignant gliomas in vitro as 
well as in vivo (Hruban  et al., 1989; Rowinsky et al., 1990).  The clinical dosage of 
paclitaxel can be dissolved in Cremophor
®
 EL (Poly-oxyethylated castor oil) and ethanol 
(50:50 v/v) and diluted before parenteral injection.  However, there are serious side-effects 
caused by Cremophor
®
 EL such as nephrotoxicity, hypersensitivity reactions, 
neurotoxicity, laboured breathing, hypotension and lethargy in the patients (Singla et al., 
2002). Although premedication with antihistamine and corticosteroids reduces 
hypersensitivity, minor side-effects have been reported in 5 to 30% of patients (Weiss et 
al., 1990). Therefore, improvements have been made in order to increase the aqueous 
solubility of paclitaxel without using Cremophor
®
 EL, in order to reduce the side effects 
caused by the drug vehicles and improve the therapeutic efficacy. The alternatives include 
the use of liposomal-based formulations (Crosasso et al., 2000; Singla et al., 2002).  
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1.11 Liposomal drug delivery system 
Liposome formulations have been extensively studied at the molecular level both in vivo 
and in vitro for drug delivery owing to their ability to increase the accumulation of 
chemotherapeutics in the tumours (Paolo et al., 2008). The amphipathic (hydrophobic and 
hydrophilic) properties of liposomes permit a wide range of drugs to be loaded into 
liposomes and hence the encapsulated drug can be protected from metabolic degradation 
(Paolo et al., 2008). Liposomes may have favourable pharmacokinetic properties in vivo 
depending on their surface properties and composition of the lipid bilayers, possibly 
providing a prolonged half-life in the blood circulation. Several studies have demonstrated 
the effects of doxorubicin liposomes (Caelyx
®
), for targeting brain tumours (Danyu et al., 
2011; Verreault et al., 2011). Danyu et al., (2011) showed the anti-glioma effects of these 
liposomes modified with angiopep-2 using another liposomal drug formulation namely 
irinotecan (Iriniphore C
TM
) and vincristine (anti-tumour drugs); and their results suggested 
tumour blood vessel normalisation of structure and function (Verreault et al., 2011).  
 
Incorporation of paclitaxel in the liposomes can reduce the drug toxicity to normal tissues 
and eliminate the hypersensitivity reactions caused by Cremophor EL vehicle. The drug 
release from liposome vesicle is comparatively rapid but not instantaneous depending on 
the alterations in therapeutic index and drug biodistribution mediated by liposomes. 
Liposomes also reduce the dose-limiting toxicity of paclitaxel by significant elevation of 
maximum tolerated dose (MTD) (Sharma et al., 1993; Cabanes et al., 1998; Fetterly and 
Straubinger, 2003). Fine et al., (2006) in a randomised study using paclitaxel and 
tamoxifen alone on brain tumours concluded that paclitaxel has higher deposition in the 
metastatic brain tumours leading to decreased expression of the P-glycoproteins, as 
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compared to tamoxifen. Sampedro et al., (1994) employed different phospholipid 
compositions like L-Dimyristoylphosphatidylcholine (DMPC) and L-
Dimyristoylphosphatidylglycerol (DMPG) with cholesterol. Multilamellar vesicles were 
prepared using the standard thin film hydration method with a drug to lipid weight ratio of 
1:15. The paclitaxel was entrapped in liposomes and used against L1210 cells (Mouse 
lymphocytic leukaemia cell line), causing higher in vitro cytotoxicity than that of 
paclitaxel alone. An in vitro study was carried out to silence VEGF expression in U251 
(Human glioblastoma astrocytoma) cell lines, by VEGF shRNA (short hairpin RNA) as an 
adjuvant therapy and treatment with various concentrations of paclitaxel-loaded liposomes. 
The results showed a significant decrease in VEGF expression of the cells making them 
sensitized to liposomal formulations in terms of apoptosis, changes in morphology, cell 
viability and formation of colonies (Yu et al., 2012).  
 
1.12 Factors affecting liposome drug delivery 
Liposomes provide several opportunities to improve cancer therapy via different 
mechanisms. Liposomes contribute in the formulation of hydrophilic and lipophilic drug 
agents and provide a sustained release of drugs to enhance or alter the pharmacokinetic 
profiles and increase the therapeutic index. Entrapment of the drug in liposomes can result 
in increased drug exposure duration of the tumour cells. Liposomal drug formulations can 
also provide specific pharmacokinetic alterations and enhance tumour deposition. 
However, liposomes may possess different properties depending on their size, surface 
charge and entrapment efficiency of the drug (Straubinger et al., 2004).  
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It was reported that the liposome size of 100-200 nm was optimum for their increased 
accumulation in tumours (Gabizon and Papahadjopoulos, 1988; Liu et al., 1992). These 
studies have emphasized that the accumulation of liposomes was dependent on their blood 
circulation time. However, the results did not prove the actual liposomal accumulation 
from blood space into the tumour cells, since their accumulation is dependent on their 
concentration present in the blood, their transfer from blood to the tumour and their contact 
with the tumour cells. Liposomal circulation time and their concentration in the blood vary 
in terms of their uptake by macrophages in the reticuloendothelial system (RES). It should 
be noted that tumour accumulation of liposomes is independent of their circulation time in 
the blood. During the initial stages of glioma, the BBB is functional around the tumour, 
but as the disease progresses, it produces a large amount of tumour angiogenesis and the 
gap of vascular endothelium goes to 50-300 nm with increased permeability (Danyu et al., 
2011). Drugs entrapped in unilamellar liposomes, which have diameters ranging from 50 
to 200 nm are small enough to escape the RES and possibly pass the BBB for targeting the 
tumour site (Uchiyama et al., 1995; Di Paolo et al., 2008). Vesicle distribution and 
clearance after systemic administration is affected by liposomes size. If the size of the 
liposome is large (>200 nm) then it can be easily cleared by the cells of RES (Lian and 
Rodney, 2000). 
 
Different types of cytotoxic drugs have been entrapped in the neutral or sterically 
stabilized liposomes for cancer therapy. However, studies have indicated that cationic 
liposomes selectively target the chronic inflammation sites and angiogenic vessels in 
tumours (Thurston et al., 1998). The reports also suggest that angiogenic endothelial cells 
bind and internalise cationic liposomes but not other liposome types. Cationic liposomes 
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can be essential in inhibiting new vessel formation or destructing the pre-existing tumour 
vessel. These liposomes can also enhance the therapeutic properties of the entrapped drug 
by anti-vascular targeting and increasing the accumulation of drug at the tumour site 
(Denekamp et al., 1984; Los et al., 2001). In another study, the influence of surface charge 
on the kinetics and uptake of the liposomes into tumour vasculature was investigated in 
vivo. The histological distribution of cationic liposomes revealed a rapid uptake in 
angiogenic tumour sites whereas anionic and neutral liposomes exhibited comparatively 
slow extravasation after intravenous injection (Krasnici et al., 2003). 
 
Drug entrapment during liposome preparation and subsequent release after administration 
are two essential properties that define the efficacy of drug delivery systems. The process 
of incorporation of the drug into the liposomes is known as drug loading. The liberation of 
the drug is the reverse phenomenon in which the drug is released from the solid state and 
become absorbed for pharmacological action. The in vitro release of the drug can be a 
quality control for investigating the internal structure of the liposome, interaction between 
the liposome and drug, and predict its in vivo behaviour (Chorny et al. 2002). Drug loading 
and drug release are dependent on the physicochemical properties of the liposomes and 
drug, and their interaction with the surrounding environments. The amount of drug loaded 
in the vesicles determines the rate and duration of drug release from the system (de Villiers 
et al., 2009). If the maximum loading capacity of the vesicle is reached, then further 
increase in the drug loading can decrease the entrapment efficiency. Changes in the 
preparation method employed and modification of the pH can also affect entrapment 
efficiency of the drug (Gaber et al., 2006; Lecaroz et al., 2006).  
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Thus, liposomes can be potential drug delivery vehicles by limiting the drug systemic 
distribution volume while avoiding any toxic effects on normal tissues, active targeting via 
tumour selective ligands on the particle surface and passive accumulation of permeable 
tumour vasculature.  
 
1.13 Aim of the thesis 
The aim of this study was to design liposomes (entrapping paclitaxel) from ethanol-based 
proliposomes and investigate their cytotoxic effects on grade IV glioma and normal glial 
cell lines. 
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CHAPTER 2:  
METHODOLOGY 
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2.1 MATERIALS 
 
List of all the chemicals and consumables obtained from different suppliers are detailed in 
Table 2.1. 
 
Table 2.1. Materials used in the preparation of liposomes and performing tissue culture 
technique 
Supplier/Country Materials 
Lipoid, Switzerland 
 SPC 
 HSPC 
 DPPC 
Lonza, Switzerland 
 EMEM (Eagle’s minimum essential 
medium) 
 Non-essential amino acid solution 
 L-glutamine (cell culture tested, 99.0 
– 101.0 %) 
Fisher Scientific, UK 
 
 Trypsin-EDTA solution 
 Ethanol (Absolute and 70%) 
 96-well plates (sterile with lids) 
 50 ml centrifuge tubes (sterile) 
 Tissue culture flask 75 cm2 (sterile) 
 Serological pipettes (sterile) 
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Sigma, UK 
 Cholesterol ≥ 99% grade 
 15 ml glass vials 
 PLL (poly-L-lysine) hydrobromide 
(molecular weight 30,000-70,000) 
 Dextran (molecular weight 5,000 
approx.) 
 DMSO (Dimethyl sulfoxide; 
suitable for culture) 
 Thiazolyl blue tetrazolium bromide 
 FBS (Fetal bovine serum) 
 PBS (Phosphate buffer saline) 
tablets 
 Trypan blue solution (0.4% liquid, 
sterile filtered) 
 Syringe filters (0.2 and 0.45 µm) 
 Syringe needles 
 Sterile pipette tip boxes 
European collection of cell cultures, UK 
 U87-MG cell line 
 SVG-P12 cell line 
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2.2 METHODS 
 
2.2.1 Preparation of liposomes using the ethanol-based proliposome method 
In this method, the lipid phase (Phospholipid: Cholesterol, 1:1 mole ratio) (50 mg) was 
dissolved in an absolute ethanol (60 mg) at 70°C for 1 min in a 15ml glass vial. This 
produced a clear ethanolic solution comprising lipid to ethanol ratio of 5:6 w/w. Paclitaxel 
was then dissolved in a range of concentrations (0.5, 1, 1.5 and 2 mg per ml i.e. 0.06, 0.12, 
0.18 and 0.24 mM per ml of liposomal formulation) within the lipid phase and ethanol to 
dissolve both lipids and drug. Aqueous (water) phase (10 ml), above the Tm of the lipid 
(Tm of SPC, HSPC and DPPC are -20°C, 50°C and 41°C respectively), was then added 
immediately to avoid lipid phase solidification. Liposomes were generated upon vigorous 
hand shaking and vortexing (Fisons Whirlimixer, UK) for 4 min. Liposomal formulations 
were then kept for annealing above the Tm of the lipids for 2 h followed by their size and 
zeta potential characterisation. This procedure of preparation and characterisation 
remained the same for all the three phospholipids (i.e. SPC, HSPC and DPPC) used 
separately in each formulation. 
 
2.2.2 Size reduction of liposomes 
Size reduction of liposomes was conducted using probe sonication. In this method, 
liposome dispersion (10 ml) was placed in a small beaker (50 ml) and the probe of the 
sonicator (Sonics Vibra-cell-CV33, USA) was immersed in the dispersion and operated at 
the highest frequency for a maximum of 10 min, while cooling the beaker in a water bath 
at regular intervals. The size of liposomes was ascertained following centrifugation (Jouan 
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Robotics A-14, France) at 10,000 rpm to remove the titanium particles leached from the 
probe. The size and polydispersity of the sonicated liposomes (in the supernatant) were 
analysed using photon correlation spectroscopy (PCS) by recording the Zaverage and 
polydispersity index (PI) respectively. Size measurements below 200 nm indicated the 
formation of SUVs and LUVs. Ideally this was accompanied by a PI of 0.3 or less. While 
performing sonication procedure, care against overheating of the sample was taken. PCS is 
explained in more details in section 2.2.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
 
2.2.3 Laser diffraction size analysis for liposomes 
Laser diffraction technique was used for size analysis of liposomes. A laser beam is 
emitted from laser-producing helium lamp so that it is incident on particles in the sample. 
The beam is then diffracted at an angle, measured by a photodetector to calculate the size 
distribution of particles based on their volume. The measurements were performed using 
the Malvern Mastersizer 2000 (Malvern instruments Ltd., UK). This was carried out by the 
addition of 70 ml of deionised water to the cone dispersion unit (Hydro2000 SM, UK) of 
the instrument. Adequate amount of sample was added to the dispersion unit in order to 
reach the green area of the obscuration range. Size and size distribution were presented as 
the volume median diameter (VMD) (50% undersize) and span respectively. Span = (90% 
undersize – 10% undersize) / VMD.  
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2.2.4 Photon correlation spectroscopy analysis for liposomes 
A drawback of laser diffraction technique is that it measures size of particles at the 
micrometres size range more accurately than particles in the submicron range. Therefore, 
photon correlation spectroscopy was used to measure the size of the liposomes in the 
nanometre range after probe sonication. This technique relies on the Brownian motion of 
the particles using the Zetasizer instrument (Zetasizer nano, Malvern Instruments Ltd., 
UK). Size and size distribution were presented by the Zaverage and polydispersity index (PI) 
respectively.  
 
 
2.2.5 Zeta potential analysis of liposomes 
Zeta potential (ZP) of the liposomes was carried out using laser Doppler velocimetry 
(LDV) principle again with the help of Zetasizer instrument (Zetasizer nano, Malvern 
Instruments Ltd., UK). The principle relies on the Doppler shift in a laser beam used to 
measure the velocity in semi-transparent or transparent fluid flows. The ZP was measured 
by adding the sample (700 µl) in a disposable zeta cell and setting the temperature at 25°C. 
 
2.2.6 Transmission Electron Microscopy (TEM) 
In this setup, a drop of liposome dispersion was placed on carbon-coated copper grids (400 
mesh) (TAAB Laboratories Equipment Ltd., UK), which was negatively stained with 1% 
phosphotungstic acid (PTA), and then viewed and photographed using a TEM (Philips CM 
120 Bio-Twin TEM, Philips Electron Optics BV, the Netherlands). 
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2.2.7 Determination of drug entrapment efficiency 
The entrapment efficiency (EE) of paclitaxel in liposomes was analysed using UV 
spectrophotometer (Jenway 7315 Spectrophotometer, UK). A calibration curve of 
paclitaxel was obtained by dissolving 10 mg of paclitaxel in 100 ml of absolute ethanol 
and serial dilution was carried out to achieve concentrations from 10 mg/100 ml to 1 
mg/100 ml. The absorbance values of the diluted samples were recorded at a wavelength 
of 270 nm. Using these absorbance values, a calibration curve of paclitaxel in mg/ 100ml 
against absorbance at 270 nm was plotted. R-squared value and a linear equation were also 
obtained.  
 
For analysis of EE of paclitaxel in liposomes, syringe filters (0.450 µm) were used to pass 
the liposomes through it at least three times, using a 5ml syringe. The filter was then 
washed using HPLC water until the solution runs clear. Then, the filter was placed in 
absolute ethanol half way and paclitaxel that did not pass with the liposomes was extracted 
using a syringe. This fraction of paclitaxel was regarded as un-entrapped. The absorbance 
of the un-entrapped paclitaxel in ethanol was measured at 270 nm using a UV 
spectrophotometer. The absorbance values were then substituted in the linear equation of 
the calibration curve to obtain the un-entrapped amount of paclitaxel in the liposomes. 
This amount was then subtracted from the total amount of paclitaxel in the liposomes to 
calculate the amount of entrapped paclitaxel. This procedure was repeated for all liposomal 
formulations. The EE of paclitaxel was calculated from the following equation: 
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                               Amount of paclitaxel entrapped (mg)  
EE (%) =                                                                                             × 100 
                     Amount of paclitaxel in liposome dispersion (mg) 
 
 
2.2.8 Cell Culture Technique 
The cell culture procedures were performed aseptically in a cell culture hood (Gelaire 
Flow Laboratories BSB 4A, Italy). All the cell culture materials were sterilised by 
autoclaving before use. The media was warmed to 37°C (Grant Instruments Sub28 water 
bath, UK) before sub-culturing the cells. The working surfaces and hands were always 
sprayed with 70% ethanol to maintain the sterile conditions and avoid the risk of 
contamination. U87-MG (grade 4 glioma, passage number 13) and SVG-P12 (glial cells, 
passage number 7) cell lines were used for the cell culture experiments. EMEM (Eagle’s 
minimum essential medium) was used as a media for growing the cells. EMEM was 
supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM L-glutamine and 0.1 mM 
non-essential amino acids. Dextran and poly-L-lysine were prepared by dissolving in 
media. MTT was prepared by dissolving 5 mg in 1 ml of PBS solution. Paclitaxel was 
dissolved in ethanol (76 µl) followed by addition of the media.   
 
 
2.2.9 Sub-culturing of the cells 
The cells (U87-MG and SVG-P12) were obtained from European Collection of cell 
cultures (ECACC, UK) and grown to 80-95% confluence, as confirmed by the inverted 
microscope (Leica Microsystems DMIL, Germany). The cells were grown in 75 cm
2
 tissue 
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culture flasks and incubated in a CO2 incubator (New Brunswick, an Eppendorf Company 
Galaxy 170S, UK) at 37°C. The U87-MG cells were passaged every 2 days and SVG-P12 
cells were passaged every 4-5 days due to the difference in growth rates. The subculture 
procedure was carried out aseptically in the cell culture hood. In this process, the medium 
was first removed using the 10ml pipette without disturbing the cells. The cells were then 
rinsed three times with PBS solution (10ml). Adherent cells were detached by adding 
0.25% trypsin-EDTA solution (2 ml) to the cells and incubated for 2 min at 37°C. Gentle 
agitation of the culture flask was carried out to help detachment of the cells. This was 
confirmed using the inverted microscope. Fresh media (4-5 ml) was added to the detached 
cells. The cell suspension was then centrifuged (Sigma 3-16PK centrifuge, Germany) at 
1000x g for 5 min. The supernatant was discarded and the cell pellet was obtained. The 
cell pellet was re-suspended three times in the appropriate media (10 ml) using a syringe 
and needle (23 G; 0.6 mm X 25 mm) to ensure disaggregation of the cells. 
 
 
2.2.10 Calculation of cell viability 
The total number of viable cells was assessed by trypan blue exclusion and the cells were 
then added to new culture flasks at the appropriate seeding density. To evaluate the viable 
cell count the homogenous cell suspension (100 µl) obtained from the sub-culture 
technique was mixed with trypan blue (100 µl). The suspension was placed on the 
Improved Neubauer Haemocytometer slide with a cover slip properly placed on top of the 
chamber. The cells were observed under a compound microscope (Nikon Eclipse e200, 
Japan) at 10x magnification. The cells that had taken up the dye (i.e. stained blue) were 
non-viable. Each large square of the haemocytometer is 1 mm
2
 in area with a depth of 0.1 
mm. Therefore, each large square provides 1 mm
2
 x 0.1 mm = 10
-4
 cm
3
 or 10
-4
 ml of cells. 
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The number of cells per large square is the number of cells x10
4
 per ml. Five large squares 
were counted followed by the addition of the number of viable cells and their average. The 
average number of cells was then multiplied by the dilution factor from stock (x2) and 10
4
. 
The following equation was used to calculate the volume of cell suspension required for 
addition to the media for the preferred cell density to seed the cells in the 96-well 
microtitre plate: 
C1 x V1 = C2 x V2 
Where, 
C1 = Concentration of cells per ml 
V1 = Volume of cell suspension required 
C2 = Density of cells per well 
V2 = Total volume required to seed the 96-well microtitre plates 
 
 
2.2.11 Seeding of 96-well plates 
The cells were sub-cultured and counted as previously detailed. A seeding density of 1 
x10
5
 cells per well was used to seed the 96-well plates for testing the compounds (i.e. 
liposomal-paclitaxel formulations, paclitaxel alone, drug-free liposomes, poly-L-lysine as 
a positive control and Dextran as a negative control). Paclitaxel was dissolved in 76 µl of 
ethanol and added to the media warmed at 37°C. The cells were seeded into the inner rows 
and columns of the 96-well plates while the outer rows and columns were seeded with PBS 
solution to avoid evaporation around the perimeter. The cells in the 96-well plates were 
grown in 5% CO2 incubator at 37°C for a period of 24 hours. The positive and negative 
controls were added (i.e. concentration of 0, 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 3, 5 
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mg/ml) in the 10 columns of the 96-well plates respectively. Zero represents media (200 
µl) without the compounds. Similarly, paclitaxel-loaded Liposomes, paclitaxel and 
paclitaxel-free liposomes were added (i.e. concentration of 0, 0.001, 0.005, 0.01, 0.05, 0.1, 
0.5, 1, 1.5, 2 mg/ml) in the 96-well plates. The cells were further incubated in 5% CO2 
incubator at 37°C for 72 h to analyse the cytotoxicity of the compounds.  
 
Similarly, seeding densities of 1 x 10
3
, 1 x 10
4
 and 1 x 10
5
 cells per well were used for 
performing the growth curves of the cell lines for a period of 7 days. Five 96-well plates 
containing 1 x 10
3
, 1 x 10
4
 and 1 x 10
5
 cells per well were grown in 5% CO2 incubator at 
37°C for a period of 24 h to 168 h (i.e. 24 h for day 1, 48 h for day 2, 72 h for day 3, 96 h 
for day 4 and 168 h for day 7 growth curves).  
 
 
2.2.12 Evaluation of cytotoxicity using colourimetric tetrazolium-based MTT assay 
3-(4,5-Dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide (MTT) assay was 
developed by Mosmann (1983) for analysing the cytotoxicity of anticancer agents and 
determination of in vitro cytotoxicity of polymers (Sgouras and Duncan, 1990). In this 
assay, a mitochondrial enzyme, succinate dehydrogenase, reduces the MTT in viable cells 
to a water-insoluble blue-coloured salt called formazan (Slater et al, 1963). MTT (20 µl) 
was added to the cells 5 h before the end of the incubation period. After the completion of 
MTT incubation, MTT-containing media (220 µl) was carefully removed to avoid removal 
of the blue crystals precipitated at the bottom of the plate. DMSO (100 µl) was then added 
to the MTT-treated cells. The plates were incubated for a further 30 min at 37°C before 
spectrophotometric analysis at 612 nm using a microtitre plate reader (Tecan GENios Plus, 
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Switzerland). The viability of the cells exposed to the compounds was expressed as the 
percentage of untreated control cells (n = 18 ± S.D.).  
 
The IC50 values (i.e. concentration resulting in 50% inhibition of cell growth) of the 
liposomes and paclitaxel were calculated graphically from the cell viability curves 
obtained by considering the absorbance of the media containing cells as 100% (Yang et 
al., 2007 and Sharma et al., 1996). 
 
 
2.2.13 Statistical analysis  
Statistical significance was measured using the analysis of variance (ANOVA) and 
student’s t-test as appropriate. All values were expressed as the mean ± standard deviation 
of the mean. Values of P < 0.05 were regarded as significantly different. 
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CHAPTER 3: 
CHARACTERISATION OF LIPOSOMES GENERATED FROM ETHANOL-
BASED PROLIPOSOMES 
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3.1 Introduction 
Proliposome technologies such as particulate-based proliposomes (Payne et al., 1986a, b) 
and ethanol (solvent)-based proliposomes (Perrett et al., 1991) have been advocated to 
overcome the instability of liposomes and provide convenient and economic options when 
compared to spray-drying or freeze-drying of liposomes. Ethanol-based proliposomes are 
ethanolic lipid solutions which, depending on the hydration procedure, generate 
oligolamellar liposomes (Perrett et al., 1991) or multilamellar vesicles (Turánek et al., 
1997), upon addition of aqueous phase above the Tm of the employed lipid.   
 
3.2 Results and Discussion 
3.2.1 Size analysis of liposomes before sonication 
The effect of paclitaxel concentrations (ranging from 0.5 mg/ml to 2 mg/ml) and the 
phospholipid compositions on the size and size distribution of the liposomes generated 
from ethanol-based proliposomes was studied. Figure 3.1 shows the effect of formulation 
on the VMD of liposomes produced from SPC, HSPC and DPPC in 1:1 mole ratio with 
cholesterol. The size differences in the paclitaxel-loaded liposomes were recorded and 
compared with paclitaxel-free liposomes. 
 
As shown in Figure 3.1, the VMD of the SPC-liposomes containing 1.5 mg/ml (3.78 µm ± 
0.08) and 2 mg/ml (3.83 µm ± 0.09) paclitaxel concentrations were slightly larger than that 
of paclitaxel-free SPC-liposomes (3.12 µm ± 0.07) (P<0.05). However, the VMD of SPC-
liposomes containing 0.5 mg/ml (3.28 µm ± 0.08) and 1 mg/ml (3.45 µm ± 0.08) paclitaxel 
concentration showed no significant difference when compared to that of paclitaxel-free 
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SPC-liposomes (P>0.05). This suggests that the VMD of SPC-liposomes increased with 
the increase in paclitaxel concentrations (1.5 and 2 mg/ml) while at low drug 
concentrations (0.5 mg/ml and 1 mg/ml) no effect on VMD of liposomes has occured. The 
average difference in the VMD of SPC-liposomes containing maximum paclitaxel 
concentration (2 mg/ml) and to that of paclitaxel-free SPC-liposomes was 0.71 µm (less 
than 1 µm).  
 
The VMD of all HSPC-liposomes containing paclitaxel were higher when compared to 
that of paclitaxel-free HSPC-liposomes (P<0.05). The VMD of paclitaxel-free HSPC-
liposomes was 3.33 µm ± 0.25, while the average VMD of HSPC-liposomes containing 
2mg/ml paclitaxel concentration was 8.78 µm ± 0.28. The VMD of HSPC-liposomes 
containing maximum paclitaxel concentration was 5.45 µm higher than paclitaxel-free 
HSPC-liposomes (P<0.05). The VMD of HSPC-liposomes containing 0.5 mg/ml paclitaxel 
concentration was 4.49 µm ± 0.26, showing an increase of 1.16 µm from the paclitaxel-
free HSPC-liposomes (P<0.05). This demonstrates the continuous increase in the size of 
HSPC-liposomes as the concentration of paclitaxel was increased. 
 
A similar trend was observed for the DPPC liposomes. The VMD of all the DPPC-
liposomes containing paclitaxel were significantly larger than the VMD of paclitaxel-free 
DPPC-liposomes (P<0.05). The average VMD of paclitaxel-free DPPC-liposomes was 
2.61 µm ± 0.16, while the average VMD of DPPC-liposomes with maximum paclitaxel 
concentration was 4.88 µm ± 0.15, showing that liposome size has almost doubled as a 
result of drug inclusion within formulation (Fig.3.1). The VMD of all the DPPC-liposomes 
increased with the increase in paclitaxel concentration but not as high as HSPC-liposomes 
did. 
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The VMD of HSPC-based liposomes were higher than those of the corresponding DPPC-
liposome formulations (P<0.05) especially when paclitaxel was included in the 
formulations. The VMD of all the paclitaxel containing DPPC-liposomes were higher than 
that of the corresponding SPC-liposome formulations (P<0.05) except for the VMD of 
DPPC-liposomes containing 0.5 mg/ml paclitaxel (3.42 µm ± 0.14), where there was no 
significant difference (P>0.05). Amongst the phospholipids used, paclitaxel concentration 
was most influential to the size of vesicles made from HSPC:Chol (1:1). This is possibly 
attributed to the higher hydrophobicity of the longer acyl chains in HSPC phospholipid 
and repulsive interactions between water molecules at the interface; causing them to 
aggregate (Zhao et al., 2005; Zhao et al., 2004; Zhao et al., 2004). 
 
Fig 3.1. Size of liposomes generated from ethanol-based proliposome formulations with 
a range of paclitaxel concentrations (n=5 ± sd) 
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3.2.2 Size distribution (Span) of liposomes before sonication 
Size distribution of liposomes was represented by measurement of Span which is a term 
introduced by Malvern Instruments Ltd to express the polydispersity of particles. In 
general, no effect was seen on the Span when paclitaxel was included within the 
proliposome formulations and the Span values of all formulations were around 2 (Fig. 3.2). 
However, the span of liposomes made from SPC:Chol (1:1) was increased (P<0.05) by 
inclusion of 0.5 mg/ml paclitaxel. No further increase of SPC-made liposomes was 
observed by inclusion of higher drug concentrations (Fig. 3.2). Paclitaxel concentration did 
not affect the span of HSPC-liposomes or DPPC liposomes and no significant difference 
(P>0.05) was detected between formulation upon inclusion of a range of paclitaxel 
concentrations (Fig. 3.2).  
 
Fig. 3.2. Size distribution of liposomes generated from ethanol-based proliposome 
formulations with a range of paclitaxel concentrations (n=5 ± sd) 
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3.2.3 Zeta potential analysis of liposomes before sonication 
The zeta potential (ZP) of all the liposomes before sonication were in the negative range 
(Fig. 3.3). A slight effect of formulation on the ZP of liposomes was observed, so that the 
ZP of formulations was in the range between approximately -1.5 and -6.5 mV. The average 
ZP of the paclitaxel-free SPC-liposomes was -1.82 mV ± 0.09 and increased to -3.57 mV ± 
0.28 upon inclusion of 0.5 mg/ml paclitaxel (P<0.05). Inclusion of higher concentrations 
of the drug tended to reduce the charge intensity and this was also observed for liposomes 
made from HSPC or DPPC (Fig. 3.3). Thus, overall, only a slight or no difference in ZP 
was seen when drug-free liposomes were compared with liposomes having the highest 
paclitaxel concentration (i.e. 2mg/ml). It is possible that changes in ZP are related to 
changes in the VMD of liposomes. Further research is needed to understand why the ZP 
tended to increase at low paclitaxel concentration and revert to the original ZP value upon 
inclusion of higher drug concentrations. 
 
The ZP of HSPC-liposomes did not show any significant difference with the increase in 
paclitaxel concentration (P>0.05). By contrast, the ZP of DPPC-liposomes displayed a 
similar effect as that of SPC-liposomes. In this case, the ZP of all the DPPC-liposomes 
containing paclitaxel increased (becoming more negative) upon inclusion of paclitaxel 
concentration. 
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Fig.3.3. Zeta potential of liposomes generated from ethanol-based proliposome 
formulations with a range of paclitaxel concentrations (n=5 ± sd) 
 
 
 
3.2.4 Size analysis of the liposomes after probe sonication 
Size of liposomes was reduced in order to convert MLVs into SUVs having a size range of 
100-200 nm. Size reduction was carried out using a probe sonicator for a maximum period 
of 10 min followed by centrifugation at 10,000 rpm to remove the titanium particles which 
were released by the probe sonicator. The sonication time was limited to 10 min in order to 
avoid the leakage of paclitaxel from liposomes and decomposition of phospholipids as a 
result of sonication induced heating. Therefore, intermittent cooling of liposomes was 
performed during sonication. 
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The effect of probe sonication on the size of liposomes was investigated. When compared 
to the size of MLVs, the size of liposomes was decreased by approximately 95% or more, 
regardless of formulation (Fig. 3.1 and Fig. 3.4). This indicates that drug inclusion and 
lipid composition did not retard size reduction and hence MLVs were successfully 
fragmented into nano-sized liposomes (100-200 nm) (Fig. 3.4). Also, liposomes made 
from HSPC:Chol (1:1) had larger size than liposomes made from DPPC:Chol (1:1) or 
SPC:Chol (1:1). This indicates that size of sonicated vesicles was affected by lipid phase 
composition. Furthermore, the effect of paclitaxel concentration on liposome size after 
sonication was minimal (Fig. 3.4). 
 
 
Fig. 3.4. Size of liposomes after probe sonication (n=5 ± sd) 
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3.2.5 Polydispersity Index (PI) of the liposomes after probe sonication 
The PI for all the liposomes was found to be below 0.3 (Fig. 3.5), indicating that 
sonication has generated liposomes with relatively narrow size distribution, regardless of 
lipid type and drug concentration. The PI of paclitaxel-free SPC-liposomes was 0.09 ± 
0.05 and it increased to 0.18 for SPC-liposomes containing the maximum paclitaxel 
concentration (Fig 3.5). The PI of HSPC-liposomes increased with 1.5 mg/ml paclitaxel 
concentration (from 0.17 ± 0.03 to 0.21 ± 0.03), whereas it decreased to 0.08 for HSPC 
vesicles having the maximum paclitaxel concentration (P<0.05) (Fig. 3.5), indicating very 
slight effect of paclitaxel on vesicle polydispersity. As shown in Fig. 3.5, it is difficult to 
correlate paclitaxel concentration with the PI value, regardless of phospholipid type. The 
low PI for all formulations indicates that the sonication time selected was appropriate and 
no further processing of the vesicles is needed.  
 
Fig. 3.5. PI of liposomes after probe sonication (n=5 ± sd) 
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3.2.6 Zeta potential analysis of liposomes after probe sonication 
The ZP of probe sonicated liposomes was studied. For SPC and HSPC made liposomes, 
very slight but significant effect (P<0.05) of drug concentration was observed on the ZP 
(Fig. 3.6). For the HSPC or SPC made liposomes, especially at low drug concentrations 
the ZP was around 0 mV, indicating a neutral surface charge. This was not the case for the 
DPPC-made vesicles since higher drug concentration made the surface charge more 
intense (i.e. more negative ZP values). The increased negativity of the ZP for the SPC and 
HSPC liposomes as a result of increasing the drug concentration demonstrated a very 
slight trend, but with statistically significant differences between the formulations (Fig. 
3.6). Compared with liposomes prior to sonication (Fig. 3.3), the ZP of paclitaxel-free 
SPC-liposomes after sonication was almost neutral whereas the ZP of SPC-liposomes 
containing the maximum paclitaxel concentration decreased in intensity by approximately 
54% as compared to the pre-sonicated liposomes (Fig. 3.3 and Fig. 3.6). This suggests that 
vesicle size has an effect on ZP values (Howard and Levin, 2010). 
 
Fig. 3.6.  Zeta potential of liposomes after probe sonication (n=5 ± sd)
 
-2.5
-2
-1.5
-1
-0.5
0
0.5
SPC:Chol (1:1) HSPC:Chol (1:1) DPPC:Chol (1:1)
Ze
ta
 p
o
te
n
ti
al
 (
m
V
) 
Formulations 
Drug-free liposomes 0.5mg/ml 1mg/ml 1.5mg/ml 2mg/ml
68 
 
3.2.7 Morphology of the liposomes 
Figures 3.7, 3.8 and 3.9 are TEM images for the 1 mg/ml paclitaxel concentrations for 
SPC, HSPC and DPPC liposomes respectively. The TEM-images were taken after probe 
sonication of liposomes and clearly showed the vesicles were SUVs. The size of SPC, 
HSPC and DPPC liposomes were approx. 125 nm, 175 nm and 155 nm and these values 
correlate with the size analysis study. Thus probe sonication method applied in this study 
was successful at converting the MLVs into liposomes in the nanometre size range. 
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Fig 3.7. TEM of SPC: Chol (1:1) liposomes containing 1 mg/ml paclitaxel concentration 
after size reduction 
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Fig. 3.8. TEM of HSPC: Chol (1:1) liposomes containing 1 mg/ml paclitaxel 
concentration after size reduction 
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Fig. 3.9. TEM of DPPC: Chol (1:1) liposomes containing 1 mg/ml paclitaxel 
concentration after size reduction 
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3.2.8 pH measurement of liposome formulations 
The effect of paclitaxel concentrations and lipid composition on the pH of liposomes was 
analysed. The pH of all SPC and HSPC liposomes was slightly acidic, while the pH of 
DPPC-liposomes was neutral to slightly basic (Fig. 3.10). It was observed that the pH of 
formulations increased by increasing the paclitaxel concentration. In case of SPC-
liposomes, the pH of paclitaxel-free liposomes was 6.06 ± 0.01 whereas the pH of 
liposomes having the maximum paclitaxel concentration was 6.72 ± 0.02 (P<0.05). 
Similarly, the pH of HSPC paclitaxel-free liposomes was 6.08 ± 0.03 while the pH of 
liposomes with maximum paclitaxel concentration was 6.84 ± 0.2 (P<0.05). For each 
paclitaxel concentration, the pH was significantly but slightly different when using 
different phospholipids. The pH of formulations was the highest for DPPC liposomes 
followed by HSPC and then SPC formulations. For each type of phospholipid, when the 
highest drug concentration formulation was compared to the drug-free one, the pH of SPC 
and HSPC liposomes increased by 0.71 and 0.76 respectively while the pH of DPPC-
liposomes increased by 0.6. The pH of SPC and HSPC-liposomes increased slightly with 
the increase in drug concentration (P<0.05). However, the pH of DPPC-liposomes was 
maintained until 1.5 mg/ml paclitaxel concentration with no significant difference. This 
study overall suggests minor differences in the pH of liposome formulations containing 
different lipids and different paclitaxel concentrations. The pH of DPPC liposomes seems 
to be the closest to pH values of the blood (pH 7.4) and from that particular perspective 
they seem to be highly appropriate excipients for the anticancer drug paclitaxel. 
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Fig. 3.10. pH of liposomes after probe sonication (n=3 ± sd) 
 
 
 
3.2.9 Entrapment efficiency of paclitaxel in liposomes 
The entrapment efficiency of paclitaxel in liposomes was analysed using a UV 
spectrophotometer (as described in Section 2.2.7). A calibration curve of paclitaxel was 
obtained by dissolving 10 mg of paclitaxel in 100 ml of ethanol and serial dilution was 
carried out to achieve drug concentrations from 10 mg/100 ml to 1 mg/ 100 ml. Figure 
3.11 shows the calibration curve of paclitaxel in mg/100 ml against absorbance at 270 nm. 
R-squared value and a linear equation were obtained to carry out the entrapment efficiency 
of paclitaxel in the liposomes. 
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Fig. 3.11. Calibration curve of paclitaxel 
 
 
 
According to Figure 3.12, the entrapment efficiency of paclitaxel decreased with the 
increase in paclitaxel concentration (P<0.05) and that was independent of phospholipid 
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The difference in zeta potential with different paclitaxel concentrations may correlate with 
the different entrapment efficiencies using liposome formulations with different lipid 
compositions. Figure 3.6 clearly demonstrates that higher drug concentrations have 
conferred more negative surface charge on the DPPC liposomes. The ability of higher drug 
concentrations to exert that effect on SPC and HSPC vesicles was less, which correlates 
well with the entrapment efficiency findings. This gives a strong indication that the 
accommodation of paclitaxel within the liposome bilayers is responsible for the negative 
zeta potential values. 
 
 
Fig. 3.12. Entrapment efficiency of liposomes by UV method (n=5 ± s.d.) 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
SPC:Chol (1:1) HSPC:Chol (1:1) DPPC:Chol (1:1)
En
tr
ap
m
e
n
t 
Ef
fi
ci
e
n
cy
 (
%
) 
Entrapped Paclitaxel (mg/ml) 
0.5 mg/ml 1 mg/ml 1.5 mg/ml 2 mg/ml
76 
 
 
3.2.10 Amount of paclitaxel entrapped in liposomes 
Figure 3.13 represents the amount of paclitaxel entrapped in 10 ml of liposome 
formulation using UV spectrophotometric analysis. The amount of paclitaxel entrapped in 
the formulations was dependent on the composition of phospholipid and paclitaxel 
concentration. In case of SPC and DPPC liposomes, the amount of entrapped paclitaxel 
increased as the concentration of paclitaxel increased in the liposomes. However, the 
amount of entrapped paclitaxel in HSPC-liposomes decreased with the highest 
concentration (20 mg/10 ml). SPC-liposomes containing 20 mg paclitaxel originally, could 
only entrap around 9.2 mg. In fact, there was no significant difference between the 
paclitaxel entrapped in SPC-liposomes containing 15 mg and 20 mg paclitaxel originally; 
which displayed a plateau phase. This indicates that SPC-liposomes might have reached a 
limit where its bilayers could not entrap more paclitaxel.  
 
HSPC-liposomes had less entrapment efficiency than SPC and DPPC-liposomes (Fig. 
3.12). The plateau phase was reached when HSPC-liposomes contained 15 mg paclitaxel 
but could only entrap around 7.3 mg. The entrapped amount for HSPC-liposomes 
containing 20 mg paclitaxel decreased to approx. 5.25 mg. The formulation started losing 
its drug entrapment property and could not entrap paclitaxel efficiently with the highest 
drug concentration as compared to the previous drug concentrations.  
 
DPPC-liposomes displayed a linear increase in entrapping paclitaxel with its increasing 
concentration. With highest paclitaxel concentration, the amount of paclitaxel entrapped 
was around 14 mg, which was higher that SPC and HSPC formulations.  
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Fig. 3.13. The amount of paclitaxel entrapped per 10 ml of formulation (n=5 ± s.d.) 
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previous studies, the drug was found to be entrapped in C1-C8 carbon atoms of the acyl 
chain i.e. in the outer hydrophobic bilayer zone of DPPC liposomes. Paclitaxel binds to the 
carbon atoms of DPPC by its C13 side chain, which is hydrophobic due to the presence of 
two aromatic rings. However, the presence of double bonds at the middle of two acyl 
chains of HSPC-liposomes causes reduction in the phase transition (54°C) and pre-
transition temperature upon inclusion of paclitaxel. This might explain the inability of 
paclitaxel to entrap efficiently into HSPC-liposomes (Campbell et al.,2001; Bernsdorff et 
al., 1999; Balasubramanian et al., 1994; Zhao et al., 2007). 
 
It has also been found that the stability of paclitaxel in saturated phospholipids is 
dependent on the chain length with DPPC (16:0) liposomes being more capable of 
entrapping higher proportions of paclitaxel than HSPC (18:0) liposomes. The interaction 
between phospholipid and paclitaxel is known to be nonspecific and dependent on the 
hydrophobic force or van der Waals force. The lower van der Waals interactions between 
hydrocarbon chains of short acyl chains leads to compact and rapid binding of paclitaxel 
with phospholipids of shorter chain ; and increased intermolecular spacing between the 
bilayers. Whereas, the stronger van der Waals interactions in HSPC-liposomes can hinder 
and act as a physical barrier for the movement of paclitaxel in the bilayers; and form 
unstable systems at air/water interface when compared to phospholipids with shorter acyl 
chain. DPPC possesses a first-order phase transition which is a transition between liquid-
expanded and liquid-condensed states whereas HSPC possess only liquid-condensed 
phase. This may be due to the high hydrophobicity of longer acyl chain phospholipids and 
repulsive interactions between water molecules at the interface (Zhao et al., 2005; Zhao et 
al., 2004; Zhao et al., 2004). 
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Some studies have suggested that naturally occurring or unsaturated phospholipid such as 
SPC can entrap hydrophobic drugs more efficiently as compared to HSPC due to their low 
gel to liquid- crystalline phase transition temperature (Tm= -20°C). The liposomes 
prepared from this type of phospholipid along with cholesterol, are flexible enough to 
entrap more hydrophobic molecules. The liposomes prepared from HSPC liposomes are 
highly rigid and can disallow the penetration of hydrophobic drugs. However, DPPC-
liposomes have shown high molecular interactions with paclitaxel due to their first-order 
phase transition behaviour. 
 
It has also been shown that, paclitaxel interaction with lipid bilayers causes an increase in 
the surface charge intensity of the liposomes. This means that, the charge intensity on the 
liposomes increases with the increase in the entrapment of paclitaxel in their vesicles. This 
property is dependent on high molecular interactions between paclitaxel and 
phospholipids. Negative charge increases the physical stability of liposomes by preventing 
their fusion and aggregation due to electrostatic repulsion (Kan et al., 2011; Zhang et al., 
2005; Kirby et al., 1980; Senior and Gregoriadis, 1982; Zolnik et al., 2010).  
 
Thus, the difference in ZP with different paclitaxel concentrations may correlate with the 
different EE using liposome formulations with different lipid compositions. Figure 3.6 
clearly represents that higher paclitaxel concentrations have conferred more negative 
surface charge on the DPPC liposomes. The ability of higher drug concentrations to exert 
that effect on SPC and HSPC vesicles was comparatively less, which correlates well with 
the EE findings. This gives a strong indication that the accommodation of paclitaxel within 
the liposome bilayers is responsible for the negative ZP values. 
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3.3 Conclusion 
Liposomes were prepared from Ethanol-based proliposomes by employing different 
phospholipid compositions: SPC, HSPC or DPPC with cholesterol in equimole ratio. 
Paclitaxel, an anti-cancer drug, was incorporated during liposome preparation. The size 
differences in the paclitaxel-loaded liposomes were recorded and compared with 
paclitaxel-free liposomes. The size of all the formulations increased with the increase in 
paclitaxel concentration. However, paclitaxel concentration was most influential to the size 
of vesicles made from HSPC:Chol (1:1),  due to the aggregation caused by higher 
hydrophobicity of their acyl chains and repulsive interactions between water molecules at 
the interface. The size distribution of the formulations remained almost the same with 
increasing paclitaxel concentration. ZP values of the formulations were in the negative 
range and showed a slight increase in the charge intensity upon inclusion of paclitaxel.  
 
Probe sonication of the liposomes was carried out in order to convert MLVs into SUVs, 
having a size range of 100 to 200 nm. The technique was successful in converting 
liposomes into nanometre range. The PI for all the liposomes was found to be below 0.3, 
indicating that sonication has generated liposomes with relatively narrow size distribution, 
regardless of lipid type and drug concentration. Phospholipid composition and drug 
concentration had minor influence on the pH of the formulations The pH of DPPC 
liposomes seemed to be the closest to pH values of the blood (pH 7.4) and from that 
particular perspective they seem to be highly appropriate excipients for the anticancer drug 
paclitaxel. 
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The entrapment efficiency of paclitaxel in DPPC liposomes was generally higher than that 
in SPC or HSPC vesicles. DPPC-liposomes were also able to entrap high amount of 
paclitaxel with increasing concentration of paclitaxel in the formulation. However, SPC-
liposomes reached a limit where they could only entrap less 50% of the original paclitaxel 
amount. HSPC-liposomes displayed a decrease in the amount of entrapped paclitaxel at 
highest drug concentration, after reaching a plateau phase. High entrapment efficiency of 
paclitaxel in DPPC-vesicles may be attributed to the fact that incorporation of paclitaxel 
makes DPPC bilayer more stable and flexible. Low van der Waals forces between the short 
acyl chains can increase the molecular interactions between paclitaxel and DPPC. The 
property of first-order phase transition possessed by DPPC is also an important factor in 
the binding of paclitaxel to the bilayers of the lipid. However, HSPC liposomes limit the 
incorporation of hydrophobic materials in their bilayers due to their long hydrophobic acyl 
chains causing repulsive reactions with water molecules at the interface. SPC is also 
known to entrap hydrophobic drugs more efficiently as compared to HSPC due to their 
low phase transition temperature. SPC-liposomes are flexible enough to entrap more 
hydrophobic molecules.  
 
ZP of the liposomes after probe sonication indicated that higher paclitaxel concentrations 
conferred more negative surface charge on the DPPC liposomes. The ability of higher drug 
concentrations to exert that effect on SPC and HSPC vesicles was comparatively less. This 
gave a strong indication that the accommodation of paclitaxel within the liposome bilayers 
was responsible for the negative ZP values and it was clearly correlated with the EE 
findings. 
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Overall, DPPC-liposomes may be the best drug carrier systems for paclitaxel because of 
their unique properties to entrap high amounts of hydrophobic drugs. 
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CHAPTER 4: 
CYTOTOXICITY STUDIES OF LIPOSOMAL FORMULATIONS ON GLIOMA 
AND NORMAL GLIAL CELLS IN VITRO 
 
 
 
 
 
 
 
 
 
 
 
 
84 
 
 
4.1 Introduction 
Tissue culture is defined as in vitro growth of cells obtained from a multicellular organism 
and is an essential tool for the understanding of cell biology of an organism at a simpler 
level. This is achieved by allowing researchers to selectively determine one variable at a 
time in a manipulated cellular environment and preventing the exposure of an organism to 
lethal and other pharmacological agents. Moreover, the continuous cell growth can be 
analysed for their development and differentiation and regulation of gene expression. 
 
Tissue culture experiments can be divided into two categories: cultures that apply primary 
cell cultures and cultures that apply secondary cell lines. Primary cultures consist of cells 
which are obtained from an animal, segregated and grown in a culture plate. But most 
primary cultures do not survive for longer periods of time. By contrast, secondary cell 
lines can grow, proliferate and become adapted to the in vitro conditions for very long 
periods of time. These clonal cell lines, grown in unlimited quantities, advocate a more 
homogenous basis of cell materials rather than do primary cultures. Nevertheless the 
indefinite growth of a cell in a culture medium suggests that it lacks the differentiated 
properties of “normal” cells and transforms into a cancer cell. Therefore, to avoid this from 
happening, the properties of the differentiated cells of an original organism must be 
understood. 
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4.2 U87-MG cell line 
U87-MG is a human glioblastoma-astrocytoma epithelial-like cell line (Fig. 4.1) first 
obtained from a grade IV cancer patient (Pomtén et al., 1968). Grade IV glioma is also 
known as glioblastoma multiforme (GBM) which is the most common malignant brain 
tumour. The cellular and growth behaviour of these cells both in situ and in vitro can be 
influenced by a wide range of expressions of growth factors and their receptors, 
representing the involvement of intricate autocrine and paracrine growth stimulatory 
pathways (APGSP) in the tumours. One such important growth factor is platelet-derived 
growth factor (PDGF). Malignant astrocytomas mainly produce PDGF A and B chain and 
their receptors, indicating that APGSP are essential in the pathogenesis of tumour in vitro 
(Maxwell et al., 1990; Hermanson et al., 1992; Nister et al., 1991).  
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Fig. 4.1. Electron Micrograph of U87-MG cells showing epithelial morphology in low 
and high confluency (Source: American Type Culture Collection (ATCC); accession no. 
HTB-14) 
 
 
 
4.3 SVG-P12 cell line 
SVG-P12 is a human glial fibroblast-like cell line. The first established culture from 
human origin was obtained by transfecting primary human fetal glial cells from brain 
material dissected from 8 to 12 week old embryos with DNA from an origin-defective-
mutant (ori
-
) of SV40 virus. This cell line is able to support the multiplication of John 
Cunningham virus (JCV). The cells may also be useful in detection and cultivation of other 
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human neurotropic viruses. This cell line has an indefinite life span in culture medium 
established by its continuous rapid multiplication and propagation using repeated tissue 
culture techniques (Major EO, United States Patent, 1987).  
 
 
4.4 Results and Discussion 
 
4.4.1 Introduction 
The media used to support the growth of U87-MG and SVG-P12 cell lines in this 
experiment was Eagle’s minimal essential medium (EMEM). The medium contain 
nutrients that are necessary for cell growth and is suitable for culturing mammalian cells in 
vitro. The media was supplemented with 10% Fetal Bovine serum (FBS), 1 mM Sodium 
pyruvate, 1 mM L-glutamine and 1% mM non-essential amino acids (Section 2.2.8). Many 
factors required for attachment and growth are provided by these additional nutrients. FBS 
is a serum supplement used for in vitro cell culture of eukaryotic cells. It contains very low 
levels of antibodies and some growth factors that are suitable for cell growth. Sodium 
pyruvate provides an additional energy source for cells and acts as a protective against the 
toxic effects of hydrogen peroxide. The amino acid L-glutamine is essential in adhesion, 
supporting the attachment of nitrogen-containing glycoproteins to cells. Non-essential 
amino acids reduce the burden of metabolism on the cells by increasing cell proliferation. 
The cells are derived from complete organisms and often cannot grow in vitro without the 
presence of hormones, amino acids and growth factors (Cooper, 2000). The procedure for 
carrying out the cell culture technique and growing conditions required for cell growth 
were described in sections 2.2.8 to 2.2.12. 
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In the present experiment, liposomal formulations of paclitaxel using different 
phospholipid compositions with equimole ratios of cholesterol (SPC:Chol, HSPC:Chol or 
DPPC:Chol) were developed. DPPC-liposomes showed a higher entrapment efficiency of 
paclitaxel than that of SPC and HSPC liposomes.  
 
In the current chapter, the cytotoxicity of different paclitaxel concentrations, loaded in the 
liposomes, against U87-MG grade IV glioma and SVG-P12 glial cell lines was determined 
using the MTT assay (Section 2.2.11). The cytotoxicity using liposomes were then 
compared to the cytotoxicity of paclitaxel alone (i.e. without liposomes). The controls used 
in the cell culture experiments were dextran (negative control, to ensure that there is no 
cytotoxic effect on the cells) and PLL (positive control, to ensure that there is cytotoxic 
effect on the cells). The difference of cytotoxicity in U87-MG and SVG-P12 cells 
following the use of liposome formulations, paclitaxel and controls were also compared.  
Growth curves of both the cell lines were also carried out for a period of 7 days to 
determine the seeding density for the cells. Therefore, seeding densities of 1 x 10
3
, 1 x 10
4
 
and 1 x 10
5
  cells per well were used to obtain the appropriate seeding density. 
 
4.4.2 Growth curve of U87-MG cells 
The growth curve of the cells was plotted by considering the day 1 absorbance (at 612 nm) 
values as 100% for each seeding density (Fig. 4.2). The cell growth was observed with 
each seeding density but at different rate. The absorbance of cells, having 1 x 10
3
 seeding 
density, was 0.0541 for day 1 and 0.1455 for day 7. On the other hand, 10
4
 seeding cells 
displayed absorbance of 0.1021 on day 1 and 0.3150 on day 7. However, the absorbance of 
cells, having 10
5
 seeding density, was 0.3308 for day 1 and 0.9936 for day 7. The cell 
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growth with these seeding densities almost tripled on the 7
th
 day but the absorbance values 
of 10
5
 cells were higher than the other cells.  
 
The growth of the cells having 10
4
 seeding density is more than that of 10
5
 seeding density 
cells by day 7 in terms of percent growth. The growth rate of 10
5
 cells decreased due to the 
fact that the cell colonies occupied the available substrate as a result of the mechanism 
known as contact inhibition (Galle et al., 2009). However, the absorbance values for 10
4
 
and 10
3
 cells are lower than that of 10
5
 cells. Higher absorbance helps in a wider 
comparison of percent cell viability while assessing the cytotoxicity of the compounds 
which are in minute to high concentrations (0.001 mg/ml through 2 or 5 mg/ml). 
Therefore, the seeding density of 10
5
 considered as appropriate for carrying out 
cytotoxicity testing. Figure 4.3 shows that 10
5
 seeding density cells are more confluent 
than 10
3
 or 10
4
 cells on day 7 of growth curve. 
 
Fig.4.2. Growth curve of U87-MG cell line for 7 day period 
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Fig.4.3. Inverted light microscope photographs of U87-MG cells, on day 7 of growth 
curve, with different seeding densities 
     
     1 x 10
3
 seeding density           1 x 10
4
 seeding density         1 x 10
5
 seeding density 
 
 
 
4.4.3 Growth curve of SVG-P12 cells 
The growth of the cells having seeding densities of 10
3
, 10
4
 and 10
5
 per well increased by 
approximately 80%, 109% and 178% respectively and displayed absorbance values of 
0.0818, 0.2142 and 0.7142 respectively on day 7 (Fig. 4.4). Higher absorbance was shown 
by the cells having cell seeding density of 10
5
. This confirms that 10
5
 would be an 
appropriate seeding density for SVG-P12 cell line to significantly compare the effects of 
formulations and controls on them. Figure 4.5 shows that 10
5
 seeding density cells are 
more confluent than 10
3
 or 10
4
 cells on day 7 of growth curve. 
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Fig.4.4. Growth curve of SVG-P12 cell line for 7 day period 
 
 
 
Fig.4.5. Inverted light microscope photographs of SVG-P12 cells, on day 7 of growth 
curve, with different seeding densities 
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After selecting the 10
5
 seeding density for the U87 cells, they were tested using a range of 
formulations to assess their cytotoxicity on the cell line. Figure 4.6 shows the various 
formulations on the viability of U87 cells by plotting the concentrations in log-scale. 
Dextran was used as a negative control. It was observed that with the increase in dextran 
concentration, the cell viability increased by approximately 9% (109% ± 0.28) for 5mg/ml 
dextran concentration (P<0.05), considering the absorbance value of the media as 100%. 
Likewise, cell growth was also observed in case of drug-free liposomes. Cell viability with 
drug-free SPC-liposomes, HSPC-liposomes and DPPC-liposomes increased by 
approximately 5%, 2% and 3% (P<0.05) respectively with 2mg/ml concentration, but not 
as high as dextran (P<0.05). The cell viability increased more in case of drug-free SPC-
liposomes as compared to the drug-free HSPC and DPPC-liposomes (P<0.05).  
 
PLL, used as a positive control, was toxic to the cells. The cell viability with PLL 
decreased by approximately 94% (viability= 6.03% ± 1.35) with 5 mg/ml concentration 
(P<0.05). Similarly, paclitaxel was also responsible for the reduction in cell growth by 
approximately 97% (viability= 3.24% ± 0.45) with the highest concentration (2 mg/ml) 
(P<0.05). Decrease in cell viability was also observed in case of paclitaxel loaded 
liposomes with increasing paclitaxel concentration in the liposomes. The viability of U87 
cells with the treatment of SPC-liposomes, HSPC-liposomes and DPPC-liposomes 
decreased by approximately 78% (21.65% ± 2.17 cell viability), 65% (45% ±0.28 cell 
viability) and 94% (5.73% ± 0.55 cell viability), respectively when 2 mg/ml paclitaxel 
concentration was used. However, paclitaxel proved to be more lethal to the U87 cells with 
2 mg/ml concentration than PLL with 5 mg/ml concentration, by approximately 3% 
(P<0.05).  
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Cytotoxicity of paclitaxel was also higher than paclitaxel in liposome formulations by 
approximately 17%, 42% and 3% when using SPC, HSPC and DPPC respectively 
(P<0.05) (Figure 4.6). Nevertheless, DPPC-liposomes showed higher cytotoxicity than 
SPC-liposomes and HSPC-liposomes by approximately 16% and 39% respectively when 
using 2 mg/ml paclitaxel (P<0.05). The reduced cytotoxicity of paclitaxel in liposome 
formulations as compared to non-liposomal paclitaxel might be attributed to sustained drug 
release upon using liposomes, or because of the nutritional values of phospholipid and 
cholesterol of liposomes. 
 
 
Fig. 4.6. Viability of U87-MG cell line tested with increasing concentrations of different 
drug compounds in 96-well plates. (n=18, N=3 ± sd)  
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Figure 4.7 shows the light microscope images of the viability of U87-MG cells after 72 
hours of incubation with paclitaxel-liposome formulations and paclitaxel alone. The 
toxicity of liposome formulations was lower than paclitaxel. However, the cell viability 
with DPPC-liposomes was less than SPC and HSPC liposomes.  High cytotoxicity of 
DPPC-liposomes might be explained by high amount of paclitaxel entrapped in their 
vesicles whereas, SPC and HSPC formulations entrapping comparatively lower amount of 
paclitaxel; displayed low cytotoxicity. 
 
Figure 4.8 represents the IC50 (half maximal inhibitory concentration) of the paclitaxel-
loaded liposomes, paclitaxel and PLL against U87-MG cells. In other words, IC50 
represents the drug concentration required for 50% inhibition of cell viability in vitro. 
Significantly higher IC50 values compared to that of paclitaxel (0.2 mg/ml ± 0.09) and PLL 
(0.3 mg/ml ± 0.05) were observed for all liposomal-paclitaxel formulations (P<0.05). 
HSPC formulation (IC50 = 1.81 mg/ml ± 0.13) was even less toxic than the SPC 
formulation (IC50 =1.15 mg/ml ± 0.25) and in turn they both were less toxic than DPPC 
paclitaxel formulation having IC50 value of 0.52 mg/ml ± 0.08 (P<0.05). 
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Fig.4.7. Inverted microscope photographs of the viability of U87-MG cells treated with 
paclitaxel-liposomal formulations and paclitaxel  
 
                  
                 Paclitaxel-SPC-Liposomes                      Paclitaxel-HSPC-Liposomes 
 
                  
               Paclitaxel-DPPC-Liposomes                                   Paclitaxel 
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Fig. 4.8. IC50  of paclitaxel-loaded liposomes, paclitaxel and PLL against U87-MG cells. 
(n=3 ± sd) 
 
 
 
The less toxic nature of liposomes may be attributed to the sustained release of paclitaxel 
when the liposomes comes in contact with medium and cells (Crosasso et al., 2000). 
Studies indicate that it takes time for the encapsulated paclitaxel to be released from the 
liposomes due to the stability of lipid bilayers as a result of inclusion of cholesterol (Yang 
et al., 2007). Increased IC50 of the liposomes entrapping paclitaxel indicate that they were 
less toxic than paclitaxel. This has been attributed to fact that the paclitaxel was retained 
within the phospholipid bilayers or attached to the surface of the liposomes. This suggest 
that ethanol-based proliposome technology has successfully generated liposomes having 
sustained release properties by demonstrating a depot effect (part of paclitaxel is stored in 
the lipid bilayer as a depot, so the longer the action of paclitaxel, the larger the depot) 
(Song et al., 2006; Horowitz et al., 1992). This indicates that, paclitaxel-loaded liposomes 
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environments; however, further studies should be conducted in vivo to find if a correlation 
with in vitro findings can be established. Also, all the liposomal formulations (paclitaxel-
loaded as well as paclitaxel-free) contained ethanol in minute quantities (76 µl) required 
during preparation. Ethanol was also used to dissolve paclitaxel along with the media of 
the cell culture. Ethanol is toxic to cells, however, the fact that U87-MG cell viability was 
increased with the treatment of paclitaxel-free liposomes proves that ethanol, present in 
such trace amount, was not responsible for cell death. Also, paclitaxel-loaded liposomes 
were toxic to the cells, indicating that it is paclitaxel which was responsible for 
cytotoxicity (Figure 4.7).  
 
The cytotoxicity exhibited by the liposome formulations had correlation with the 
entrapment efficiency studies. DPPC formulations displayed higher cytotoxicity compared 
to SPC and HSPC formulations, and these results were consistent with the repetition of 
experiments. Studies indicate that increased local concentration of the drug at the cellular 
site is dependent on the amount of drug present in the liposomes. The efflux of drug from 
HSPC formulations was comparatively lower than SPC and DPPC formulations. High 
entrapment efficiency of paclitaxel in the liposomes would lead to high intracellular uptake 
of paclitaxel in vitro. This might explain the difference in the cytotoxic effects of the 
paclitaxel-loaded liposomal formulations (Gregoriadis, 1988). 
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4.4.5 Effects of liposomes, paclitaxel and controls on SVG-P12 cells 
Using 10
5 
seeding density for the SVG-P12 cells, they were tested with different 
compounds to assess their cytotoxicity. Figure 4.9 shows the effect of formulation on the 
viability of SVG-P12 cells by plotting concentrations in log-scale. As for U87-MG cells, 
dextran was used as a negative control. It was observed that with the increase in the 
dextran concentration, the cell viability increased by approximately 13% (113% ± 0.75) 
using 5mg/ml dextran (P<0.05), considering the absorbance value of the media as 100%. 
Likewise, cell growth was observed in case of drug-free liposomes. Cell viability increased 
by 2% using drug-free SPC-liposomes drug-free HSPC-liposomes and by 3% using drug-
free DPPC-liposomes respectively when the liposome concentration was 2mg/ml, but not 
as high as dextran (P<0.05). There was no significant difference between the effects of 
drug-free SPC-liposomes, HSPC-liposomes and DPPC-liposomes (P>0.05).  
 
PLL, as a positive control, was toxic to SVG-P12 cells. The viability of the cells when 
treated with PLL, decreased by approximately 96% (cell viability of 3.98% ± 0.66) using 5 
mg/ml concentration (P<0.05). Similarly, paclitaxel was responsible for the reduction in 
cell growth by approximately 78% (cell viability of 21.77% ± 1.05) with the highest 
concentration (2 mg/ml) (P<0.05). The decrease in cell viability was also observed in case 
of paclitaxel loaded liposomes with increasing liposome concentrations. The viability of 
SVG-P12 cells, when treated with paclitaxel-loaded SPC-liposomes, HSPC-liposomes and 
DPPC-liposomes, decreased by approximately 44% (cell viability of 56.17% ± 1.2), 38% 
(62.39% ± 1.95 cell viability) and 45% (55.12% ± 2.06 cell viability), respectively using 2 
mg/ml paclitaxel concentration. Paclitaxel proved to be less lethal to the SVG-P12 cells 
than PLL (P<0.05). However, cytotoxicity of paclitaxel and PLL was higher than all 
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paclitaxel loaded liposomes (P<0.05). The results suggest that liposomal formulations of 
paclitaxel are less toxic to glial cells than to U87 cells by approximately 30%, 20% and 
45% when treated with paclitaxel-loaded SPC-liposomes, HSPC-liposomes and DPPC-
liposomes respectively.  
 
 
Fig.4.9. Viability of SVG-P12 cell line tested with increasing concentrations of different 
formulations in 96-well plates. (n=18, N=3 ± sd)  
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Figure 4.10 shows the light microscope images of the viability of SVG-P12 cells after 72 
hours of incubation with paclitaxel-liposome formulations and paclitaxel alone. The 
toxicity of liposome formulations was lower than paclitaxel. However, paclitaxel-
liposomes and paclitaxel-alone were less toxic to SVG-P12 cells than U87-MG cells. 
 
The IC50 of paclitaxel and PLL was 0.87 mg/ml ± 0.11 and 0.3 mg/ml ± 0.06 respectively. 
Paclitaxel was less toxic to the SVG-P12 cells as compared to the U87 cells by 18%. 
Liposomal formulations were also toxic to the SVG-P12 cells but their toxicity was less 
than 50%. This implies that the liposomal formulations would need more than 2 mg/ml 
paclitaxel to kill 50% of SVG-P12 cells. Thus, IC50 of liposome formulations could not be 
determined. 
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Fig.4.10. Inverted microscope photographs of the viability of SVG-P12 cells treated with 
paclitaxel-liposomal formulations and paclitaxel 
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Paclitaxel have been known to be cytotoxic on a wide variety of human cell lines such as 
malignant brain tumour cells (U87-MG, U373, H80 and D324), breast adenocarcinoma 
(MCF-7), lung carcinoma (A549), cervical carcinoma (HeLa), colon adenocarcinoma (HT-
29), ovarian adenocarcinoma (OVG-1) and pancreatic adenocarcinomas (PC-Sh and PC-
Zd); and rat brain tumour cell lines (9L and F98) (Cahan et al., 1994; Liebmann et al., 
1993). The reason for increased cytotoxicity by paclitaxel in vitro have been credited to the 
fact that paclitaxel acts as an inhibitor of cell proliferation in vitro by interfering with the 
cell cycle development (Straubinger et al., 2004; De Brabander et al., 1981). Paclitaxel 
works by blocking the cell cycle at G2/M phase and altering the arrangement of spindle 
microtubules thereby causing cell death (Jordan et al., 1993). Similar anti-mitotic 
mechanism, upon treatment with paclitaxel, may have taken place suggesting the decrease 
in viability of U87-MG and SVG-P12 cell lines.  
 
However, SVG-P12 cells showed less sensitivity to paclitaxel and paclitaxel-loaded 
liposomes than U87-MG cells. This may be due to the reason that the rate at which tumour 
cells are killed is dependent on their growth curve. Growth curve analysis of the cell lines 
plays a crucial role in understanding the cell proliferation and effect of anti-tumour agents 
on them. Tumour cells that display a rapid and unregulated growth are more sensitive to 
the cytotoxic effects of anti-mitotic and anti-tumour drug such as paclitaxel and exposed to 
mitotic cell death by rapid intracellular uptake of the drug. Paclitaxel interfere with DNA 
replication in the cell cycle and inhibits the mitotic division of the cells attempting to 
divide. While performing tissue culture experiments, U87-MG cells reached high 
confluency (80-90%) in 2 days while SVG-P12 cells achieved the similar confluency in 4-
5 days, for further sub-culturing of the cells. The growth and division of normal cells such  
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as SVG-P12, in tissue culture conditions, are similar to that of U87-MG cells. However, 
the growth rate of normal cells decreases once they cover the bottom of the culture flask 
and remain as a monolayer. Growth inhibition may be caused by the exhaustion of growth 
factors in the medium. On the other hand, glioma cells continue to grow until they overlap 
with surrounding cells and form clumps. This may be due to the fact that they are 
unresponsive to the signals that cause the ceasing of growth and division of their normal 
counterparts. This might explain the rapid decrease in the viability of U87-MG cells as 
compared to that of SVG-P12 cells when treated with paclitaxel and liposome 
formulations (Karp, 2002). It can be observed that SVG-P12 cells treated with paclitaxel-
loaded liposomes were less sensitive to the effect of paclitaxel at 2 mg/ml as compared to 
the increased toxicity in U87-MG cells by paclitaxel (Figures 4.6, 4.7, 4.8, 4.9 and 4.10).  
 
It was also observed that the drug-free formulations did not show any toxic effect on the 
glioma as well as normal glial cell lines. Studies have shown that drug-free liposomes 
displayed non-toxic effect or effect equal to that of negative control on AsPC1 cells 
(Human pancreatic tumour cell line) in vitro (Graeser et al., 2009). This may be due to the 
fact that liposomes are prepared from naturally occurring substances such as phospholipids 
and cholesterol which are major components of biological membranes essential for cellular 
functions. Phosphatidylcholine forms a major component of the cell membranes and are 
found in the exoplasmic membrane leaflets. In fact, liposome vesicles might enhance the 
efficacy of the drugs by binding to the cells and releasing them in a sustained manner (al-
Suwayeh et al., 1996; Lasic et al., 1995). 
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4.5 Conclusion 
This study was aimed to investigate the in vitro cytotoxicity of paclitaxel-loaded liposome 
formulations and paclitaxel on a grade IV glioma (U87-MG) cell line and a normal glial 
(SVG-P12) cell line. The cytotoxicity study was carried out using MTT reduction assay. 
Liposome formulations and paclitaxel-alone had toxic effects on both the cell lines. 
However, liposomes were less toxic to the cells compared to paclitaxel. This is attributed 
to the sustained release of paclitaxel from the liposomes due to the stability of the lipid 
bilayers. The drug was retained for a longer time in the liposome vesicles. This indicated 
that ethanol-based proliposome technology was successful in generating liposomes having 
sustained release properties by demonstrating a depot effect. Paclitaxel-loaded liposomes 
having a size of approximately 100 to 200 nm would remain stable in biological 
environments.  
 
The cytotoxicity exhibited by the liposome formulations had correlation with the 
entrapment efficiency studies. DPPC-liposomes displayed higher cytotoxicity compared to 
SPC and HSPC formulations, and these results were consistent with the repetition of 
experiments. Studies indicate that increased local concentration of the drug at the cellular 
site is dependent on the amount of drug present in the liposomes. The efflux of drug from 
HSPC formulations was comparatively lower than SPC and DPPC formulations. High 
entrapment efficiency of paclitaxel in the liposomes would lead to high intracellular uptake 
of paclitaxel in vitro, with sustained release.  
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Paclitaxel is an anti-mitotic and anticancer drug. It inhibits the cell proliferation in vitro by 
interfering with the cell cycle development. This might explain the toxic nature of 
paclitaxel against U87-MG and SVG-P12 cells. However, paclitaxel was relatively less 
toxic to SVG-P12 cells than U87-MG cells. This may be due to the fact that the rate at 
which tumour cells are killed is dependent on their growth curve. Growth curve analysis of 
the cell lines played a crucial role in understanding the cell proliferation and effect of anti-
tumour agents on them. Tumour cells that display a rapid and unregulated growth are more 
sensitive to the cytotoxic effects of anti-mitotic and anti-tumour drug such as paclitaxel 
and exposed to mitotic cell death by rapid intracellular uptake of the drug. Paclitaxel 
interfere with DNA replication in the cell cycle and inhibits the mitotic division of the cells 
attempting to divide. Since, the growth of glioma cells in vitro is uncontrolled compared to 
normal glial cells, paclitaxel may have interfere with DNA replication in the cell cycle and 
inhibited the mitotic division of the glioma cells rapidly. 
 
Drug-free liposomes proved to be non-toxic to both the cell lines by showing effect similar 
to that of negative control (Dextran). Liposomes are prepared from naturally occurring 
substances such as phospholipids and cholesterol, which are major components of 
biological membranes essential for cellular functions. Phosphatidylcholine forms a major 
component of the cell membranes and are found in the exoplasmic membrane leaflets. 
Liposome vesicles might in turn enhance the efficacy of the entrapped drugs by releasing 
them in a sustained manner. 
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Finally, ethanol-based proliposomes employed using different phospholipids composition 
and drug concentration may provide a potential delivery for both hydrophobic and 
hydrophilic drugs. The properties of different liposome formulations were essential in 
understanding their drug delivery mechanism in vitro. However, to ascertain whether the 
correlation with in vitro findings can be established, further studies should be conducted in 
vivo.  
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CHAPTER 5: 
GENERAL CONCLUSIONS AND FUTURE STUDIES 
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5.1 Introduction 
It is well established that liposomes can deliver paclitaxel and provide beneficial effects on 
the pharmacology and toxicology of the drug. Paclitaxel-loaded liposome formulations not 
only avoid the acute toxicity of Cremophor EL vehicle but also change the drug efficacy 
(Sharma et al., 1993; Sharma et al., 1995; Sharma et al., 1996; Sharma et al., 1997; 
Cabanes et al., 1998). Furthermore, liposomes prepared from ethanol-based proliposomes 
can overcome the difficulty of manufacturing liposomes on a large scale. Moreover, 
proliposomes offer an approach to avoiding the instability problems of liposomes in 
aqueous media (Kensil and Dennis, 1981; Grit et al., 1989; Hunt and Tsang, 1981).  
 
In this project, paclitaxel-loaded liposomes were prepared from ethanol-based 
proliposomes. Ethanol-based proliposomes are ethanolic solutions of phospholipid which 
produce liposomes on addition of aqueous phase above the Tm of the lipid phase (Perrett et 
al., 1991). It was observed that the physicochemical properties of formulations, entrapment 
efficiency of paclitaxel in the liposomes and the cytotoxicity of the formulations were 
influenced by lipid composition (SPC:Chol, HSPC:Chol and DPPC:Chol in 1:1 mole ratio) 
and the concentration of paclitaxel in liposome dispersions. 
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5.2 Charactersation of liposomes before sonication 
Liposomes prepared from ethanol-based proliposomes were MLVs as shown by TEM 
study. The VMD of SPC, HSPC and DPPC liposomes increased with increasing paclitaxel 
concentration. Compared with paclitaxel-free liposomes, vesicles containing paclitaxel 
(2mg/ml) had VMD measurements that were larger by approximately 0.7, 5.5 and 2.2 µm 
respectively (Section 3.2.1). Amongst the phospholipids used, paclitaxel concentration was 
most influential to the size of vesicles made from HSPC:Chol (1:1). This is possibly 
attributed to the higher hydrophobicity of the longer acyl chains in HSPC phospholipid 
and repulsive interactions between water molecules at the interface; causing them to 
aggregate. The ZP values of all formulations had negative values. Inclusion of higher 
concentrations of paclitaxel tended to reduce the charge intensity of SPC and DPPC 
liposomes while the ZP of HSPC-liposomes did not show any significant difference with 
the increase in paclitaxel concentration (Section 3.2.3). The size distribution of HSPC and 
DPPC liposomes did not show any significant increase with the increase in paclitaxel 
concentration.  
 
 
5.3 Characterisation of liposomes after sonication 
MLVs were successfully fragmented into nano-sized liposomes (100-200 nm) using probe 
sonication for 10 min. It was observed that the effect of paclitaxel concentration on 
liposome size after sonication was minimal. HSPC liposomes had larger size than 
liposomes prepared from DPPC and SPC suggesting the influence of lipid composition 
(Section 3.2.4). The PI of all the formulations was below 0.3, indicating that sonication 
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time selected was appropriate to form homogenous liposomes (Section 3.2.5). The ZP of 
SPC and HSPC liposomes was slightly influenced by paclitaxel concentration. At low drug 
concentrations, the ZP of these formulations was around 0 mV, indicating a neutral surface 
charge. However, DPPC-liposomes had more intense surface charge upon using higher 
paclitaxel concentrations (Section 3.2.6).  
 
 
5.4 pH of liposome formulations 
For each paclitaxel concentration, the pH of liposomes was slightly different when using 
different phospholipid compositions (Section 3.2.8). The pH of all SPC and HSPC 
liposomes was acidic, while it was neutral to slightly basic for DPPC-liposomes. For each 
phospholipid type, when the highest paclitaxel concentration formulation was compared 
with the paclitaxel-free ones, the pH increased. The results suggest that the pH of 
formulations were influenced by paclitaxel concentration and lipid composition. The pH of 
DPPC liposomes was found to be the closest to the pH of blood (pH 7.4) making DPPC 
liposomes highly appropriate vehicles for the anticancer hydrophobic drug paclitaxel. 
 
 
5.5 Entrapment efficiency of paclitaxel in liposomes 
The entrapment efficiency of paclitaxel in liposomes, analysed using a UV 
spectrophotometer, decreased with the increase in paclitaxel concentration. It was 
observed that the entrapment of paclitaxel in DPPC liposomes (85.6% ± 2.7) was generally 
higher than that in SPC (75% ± 5.3) or HSPC (67.2% ± 4.7) vesicles when low drug 
concentration was used. The entrapment efficiency of the drug in DPPC liposomes, using 2 
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mg/ml paclitaxel concentration, decreased by only around 15% compared to a decreased 
by 30% and 41% for SPC and HSPC liposomes respectively (Section 3.2.9 and 3.2.10).  
 
The difference in ZP with different paclitaxel concentration was in correlation with the 
difference in entrapment efficiency using formulations with different lipid phases. The ZP 
values in Fig 3.6 notified that higher paclitaxel concentrations was able to confer more 
negative surface charge on the DPPC liposomes while the capability of paclitaxel to exert 
that effect on SPC and HSPC liposomes was less. This associated well with the entrapment 
efficiency findings. This also provides a strong indication that incorporation of paclitaxel 
in the bilayers of liposomes accounts for the negative ZP values. Previous studies indicate 
that incorporation of paclitaxel in DPPC-liposomes makes DPPC bilayer more stable and 
flexible. Low van der Waals forces between the short acyl chains can increase the 
molecular interactions between paclitaxel and DPPC. The property of first-order phase 
transition possessed by DPPC is also an important factor in the binding of paclitaxel to the 
bilayers of the lipid. However, HSPC liposomes limit the incorporation of hydrophobic 
materials in their bilayers due to their long hydrophobic acyl chains causing repulsive 
reactions with water molecules at the interface. SPC is also known to entrap hydrophobic 
drugs more efficiently as compared to HSPC due to their low phase transition temperature. 
SPC-liposomes are flexible enough to entrap more hydrophobic molecules. 
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5.6 Tissue culture findings 
The cytotoxicity of paclitaxel-loaded liposomes against U87-MG grade IV glioma and 
SVG-P12 glial cell lines was determined using MTT assay. The cell seeding density of 10
5
 
cells/well was chosen for both the cell lines to carry out the cytotoxicity studies (Section 
4.4.2 and 4.4.3). It was observed that paclitaxel alone was more toxic to U87-MG and 
SVG-P12 cells than liposomes formulations. However, it was toxic by 17% and 42% 
containing SPC and HSPC liposomes. DPPC-liposomes showed higher cytotoxicity than 
SPC and HSPC formulations. The results were in correlation with the entrapment 
efficiency findings. However, paclitaxel-free liposomes increased the viability of U87 cells 
indicating the non-toxic nature of drug-free liposomes. 
 
In case of SVG-P12 cells, the cytotoxicity of liposomal formulations was well below 50% 
while paclitaxel was significantly toxic to the glial cells (around 91%). Liposomes proved 
to be less toxic to SVG-P12 cells than U87 cells indicating the specific targeting of 
liposomes in terms of toxicity. Again, paclitaxel-free liposomes contributed to the cell 
viability of SVG-P12 cells. 
 
Liposome formulations and paclitaxel-alone had toxic effects on both the cell lines. 
However, liposomes were less toxic to the cells compared to paclitaxel. This is attributed 
to the sustained release of paclitaxel from the liposomes due to the stability of the lipid 
bilayers. The drug was retained for a longer time in the liposome vesicles. This indicated 
that ethanol-based proliposome technology was successful in generating liposomes having 
sustained release properties by demonstrating a depot effect. Paclitaxel-loaded liposomes 
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having a size of approximately 100 to 200 nm would remain stable in biological 
environments.  
 
The cytotoxicity exhibited by the liposome formulations had correlation with the 
entrapment efficiency studies. DPPC-liposomes displayed higher cytotoxicity compared to 
SPC and HSPC formulations, and these results were consistent with the repetition of 
experiments. Studies indicate that increased local concentration of the drug at the cellular 
site is dependent on the amount of drug present in the liposomes. The efflux of drug from 
HSPC formulations was comparatively lower than SPC and DPPC formulations. High 
entrapment efficiency of paclitaxel in the liposomes would lead to high intracellular uptake 
of paclitaxel in vitro, with sustained release.  
 
Paclitaxel is an anti-mitotic and anticancer drug. It inhibits the cell proliferation in vitro by 
interfering with the cell cycle development. This might explain the toxic nature of 
paclitaxel against U87-MG and SVG-P12 cells. However, paclitaxel was relatively less 
toxic to SVG-P12 cells than U87-MG cells. This may be due to the fact that the rate at 
which tumour cells are killed is dependent on their growth curve. Growth curve analysis of 
the cell lines played a crucial role in understanding the cell proliferation and effect of anti-
tumour agents on them. Tumour cells that display a rapid and unregulated growth are more 
sensitive to the cytotoxic effects of anti-mitotic and anti-tumour drug such as paclitaxel 
and exposed to mitotic cell death by rapid intracellular uptake of the drug. Paclitaxel 
interfere with DNA replication in the cell cycle and inhibits the mitotic division of the cells 
attempting to divide. Since, the growth of glioma cells in vitro is uncontrolled compared to 
normal glial cells, paclitaxel may have interfered with DNA replication in the cell cycle 
and inhibited the mitotic division of the glioma cells rapidly. 
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Drug-free liposomes proved to be non-toxic to both the cell lines by showing effect similar 
to that of negative control (Dextran). Liposomes are prepared from naturally occurring 
substances such as phospholipids and cholesterol, which were useful for growing the cells. 
They are major components of biological membranes essential for cellular functions and 
regulating cell cycle. Phosphatidylcholine forms a major constituent of the cell 
membranes, and are found in the exoplasmic membrane leaflets. Liposome vesicles might 
in turn enhance the efficacy of the entrapped drugs by releasing them in a sustained 
manner and prove to be non-toxic. 
 
These studies have demonstrated that ethanol-based proliposomes offer an appropriate 
means of generating drug delivery systems. DPPC-liposomes may be the best drug carrier 
systems for paclitaxel because of their unique properties to entrap high amounts of 
hydrophobic drugs.  
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5.7 Future studies 
Due to time restrictions, several studies have not been performed. For instance, it would be 
essential to understand why the ZP of liposomes before sonication tended to increase at 
low paclitaxel concentration and revert to the original ZP value upon inclusion of higher 
paclitaxel concentrations which were consistent with repetition of the experiment 5 times.  
 
Ethanol-based proliposomes containing different lipid compositions and varying paclitaxel 
concentrations should be investigated for their in vivo behaviour in terms of drug release, 
clearance and biodistribution to ascertain whether the correlation with in vitro findings can 
be established. 
 
Applying different liposomal-based systems may also be helpful to understand the 
differences in the behaviour of liposomes in blood circulation. Also, applying gene therapy 
via liposomes for glioma treatment may produce desired results. 
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